[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 394
1. Secondino S, Citterio A, Pedrazzoli P, Funaioli C, Scialfa GG, Siena S: Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. Anticancer Res; 2008 Nov-Dec;28(6B):3991-2
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
  • We report on radiological abnormalities resembling recurrent tumor in adult medulloblastoma receiving intensified chemotherapy and radiotherapy.
  • Evidence provided in this paper confirms previous reports in the pediatric population and suggests that neuroradiologist and medical oncologists should be aware of new possible radiological findings related to aggressive treatments for brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192661.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


2. Lai R: Survival of patients with adult medulloblastoma: a population-based study. Cancer; 2008 Apr 1;112(7):1568-74
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with adult medulloblastoma: a population-based study.
  • BACKGROUND: Adult medulloblastoma accounts for less than 1% of adult intracranial tumors.
  • RESULTS: Four hundred fifty-four patients with adult medulloblastoma were diagnosed from 1973-2004 in the 17 regions covered by SEER.
  • [MeSH-major] Cerebellar Neoplasms / mortality. Medulloblastoma / mortality
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Prognosis. Registries. SEER Program. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278809.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Mittal P, Gupta K, Saggar K, Kaur S: Adult medulloblastoma mimicking Lhermitte-Duclos disease: can diffusion weighted imaging help? Neurol India; 2009 Mar-Apr;57(2):203-5
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma mimicking Lhermitte-Duclos disease: can diffusion weighted imaging help?
  • Lhermitte-Duclos disease, also known as dysplastic cerebellar gangliocytoma, is a rare cerebellar benign tumor with characteristic appearance of thickened cerebellar folia giving a laminated or striated appearance, quite diagnostic of the condition.
  • We had seen a patient with medulloblastoma with imaging findings suspicious for thickened cerebellar folia reminiscent of Lhermitte-Duclos disease.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Hamartoma Syndrome, Multiple / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Contrast Media. Humans. Magnetic Resonance Imaging. Male. Young Adult

  • Genetic Alliance. consumer health - Lhermitte-Duclos disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439857.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


Advertisement
4. Rodriguez FJ, Eberhart C, O'Neill BP, Slezak J, Burger PC, Goldthwaite P, Wu W, Giannini C: Histopathologic grading of adult medulloblastomas. Cancer; 2007 Jun 15;109(12):2557-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic grading of adult medulloblastomas.
  • BACKGROUND: Histopathologic evaluation of the degree and extent of anaplasia is a useful prognostic parameter in pediatric medulloblastomas.
  • Whether the same applies to adult medulloblastomas is not known.
  • METHODS: The study included 74 adult patients with histologically confirmed medulloblastomas and retrospectively reassessed 67 cases with available slides for the presence of nodularity, collagen deposition (desmoplasia without nodules), and degree and extent of anaplasia.
  • CONCLUSIONS: The incidence of severe anaplasia in adult medulloblastomas is lower than in the pediatric population.
  • [MeSH-major] Cerebellar Neoplasms / classification. Medulloblastoma / classification
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Humans. Immunoenzyme Techniques. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17487854.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


5. Cakar M, Aksoy S, Kilickap S, Harputluoglu H, Erman M: Procarbazine, lomustine, vincristine combination may be effective in adult medulloblastoma patients with systemic metastases. J Neurooncol; 2005 Nov;75(2):233-4
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Procarbazine, lomustine, vincristine combination may be effective in adult medulloblastoma patients with systemic metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Lomustine / therapeutic use. Lymphatic Metastasis / pathology. Medulloblastoma / drug therapy. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132496.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


6. Privitera G, Acquaviva G, Ettorre GC, Spatola C: Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature. J Oncol; 2009;2009:247873

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature.
  • Medulloblastoma is a rare tumor in central nervous system, with an even rarer occurrence in adulthood.
  • We report the case of a 51-year-old man with recurrent medulloblastoma.
  • The aim of this report is to show that recurrent medulloblastoma in adults can be approached with a multimodality treatment and that antiangiogenic therapy should have a role in the management of this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Pediatr Res. 2008 May;63(5):584-90 [18427305.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):384-92 [17704359.001]
  • [Cites] Paediatr Drugs. 2007;9(2):81-96 [17407364.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):169-76 [9266455.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):433-40 [1847194.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • (PMID = 20111585.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2804042
  •  go-up   go-down


7. Infante JR, Rayo JI, Serrano J, Domínguez ML, García L, Sánchez R: Adult medulloblastoma relapse visualized by in-111 octreotide scintigraphy. Clin Nucl Med; 2006 Oct;31(10):633-5
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma relapse visualized by in-111 octreotide scintigraphy.
  • [MeSH-major] Cerebellar Neoplasms / radionuclide imaging. Medulloblastoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Octreotide / analogs & derivatives. Pentetic Acid / analogs & derivatives
  • [MeSH-minor] Adult. Female. Humans. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985373.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 111In-octreotide, DTPA(0)-; 0 / Radiopharmaceuticals; 7A314HQM0I / Pentetic Acid; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Figols-Ladrón de Guevara J, Lafuente-Sánchez JV: [The medulloblastoma]. Rev Neurol; 2006 Aug 16-31;43(4):213-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The medulloblastoma].
  • INTRODUCTION AND DEVELOPMENT: Medulloblastoma is a cerebellar small cell tumor, whose ancestor cell has not been yet identified in the human normal embriology: its exact origin is, in fact, still unknown.
  • Nevertheless, one of the most acceptable possibilities facing the origin of the tumor is the remaining rests of cerebellar outer granular sheet.
  • It is a predominantly infantile tumor, less frequent in young adults, and World Health Organization (WHO) classification has assignated grade IV of malignancy.
  • In this publication of the WHO, medulloblastomas have been subclassified into: classic, desmoplastic, medulloblastomas with extensive nodularity and advanced neuronal differentiation and large cell medulloblastomas.
  • [MeSH-major] Brain Neoplasms. Medulloblastoma
  • [MeSH-minor] Adult. Cerebellum / pathology. Chromosomes, Human, Pair 17. Diagnosis, Differential. Humans. Isochromosomes. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883510.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


9. Schiebel P, Stippich C, Unterberg A: [Adult medulloblastoma]. Rofo; 2010 Sep;182(9):808-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult medulloblastoma].
  • [Transliterated title] Adultes Medulloblastom.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Cerebellum / pathology. Cerebellum / surgery. Contrast Media / administration & dosage. Craniotomy. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20544581.001).
  • [ISSN] 1438-9010
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


10. Ueba T, Kadota E, Kano H, Yamashita K, Kageyama N: MATH-1 production by an adult medulloblastoma suggestive of a cerebellar external granule cell precursor origin. J Clin Neurosci; 2008 Jan;15(1):84-7
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MATH-1 production by an adult medulloblastoma suggestive of a cerebellar external granule cell precursor origin.
  • Radiological, histological and molecular findings in an uncommon adult case of cerebellar medulloblastoma suggested an external granular cell precursor origin.
  • Postoperative neuronal imaging studies showed that the tumor located in the cerebellar folia had been removed totally.
  • Pathological examination identified it as a desmoplastic medulloblastoma with subpial and subarachnoid infiltration and some infiltration into the molecular and granular layer via the perivascular space.
  • Polymerase chain reaction and immunohistochemical findings revealed the presence of MATH-1, expressed in cerebellar external granule cell precursors during fetal development, in the tumor cells.
  • These findings suggest that the tumor arose from external granule cell precursors of the cerebellum and that it was therefore of neuronal lineage.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cerebellar Neoplasms / metabolism. Cerebellar Neoplasms / pathology. Medulloblastoma / metabolism. Medulloblastoma / pathology. Neurons / physiology
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Neoplastic. Humans. Magnetic Resonance Imaging / methods. Neoplastic Stem Cells / physiology. Phosphopyruvate Hydratase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032051.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / ATOH1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


11. Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U, Weller M: Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol; 2005 Mar;252(3):291-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.
  • Adult medulloblastoma is a rare tumor with few retrospective studies published so far.
  • This study reports therapy and outcome in all adult (>or=16 years old) medulloblastoma (n=34) and supratentorial primitive neuroectodermal tumor (PNET) patients (n=2) treated in 2 neuro-oncological centers between 1976 and 2002.
  • In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients.
  • As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4(th) ventricle indicates a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Demography. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Drug Therapy / methods. Female. Humans. Male. Middle Aged. Radiotherapy, High-Energy / methods. Recurrence. Regression Analysis. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189725.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Germanwala AV, Mai JC, Tomycz ND, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD: Boost Gamma Knife surgery during multimodality management of adult medulloblastoma. J Neurosurg; 2008 Feb;108(2):204-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boost Gamma Knife surgery during multimodality management of adult medulloblastoma.
  • OBJECT: The aim of this paper was to determine prognostic factors for adult medulloblastoma treated with boost Gamma Knife surgery (GKS) following resection and craniospinal irradiation.
  • METHODS: The authors performed a retrospective analysis of 12 adult patients with histologically proven medulloblastoma or supratentorial primitive neuroectodermal tumor who between February 1991 and December 2004 underwent >or=1 sessions of GKS for posttreatment residual or recurrent tumors (6 tumors in each group).
  • Stereotactic radiosurgery was applied to residual and recurrent posterior fossa tumor as well as to foci of intracranial medulloblastoma metastases.
  • The mean GKS-treated tumor volume was 9.4 cm3 (range 0.5-39 cm3).
  • RESULTS: Following adjunctive radiosurgery, 5 patients had no evidence of tumor on magnetic resonance (MR) imaging, 3 patients had stable tumor burden on MR imaging, and 4 patients had evidence of tumor progression locally with or without intracranial metastases.
  • All patients with tumor progression died.
  • The majority of patients who achieved tumor eradication (80%) and tumor stabilization (67%) after GKS had residual tumor as the reason for their referral for GKS.
  • The best outcomes were attained in patients with residual disease who were younger, had smaller tumor volumes, had no evidence of metastatic disease, and had received higher cumulative GKS doses.
  • CONCLUSIONS: Single or multiple GKS sessions were a well-tolerated, feasible, and effective adjunctive treatment for posterior fossa residual or recurrent medulloblastoma as well as intracranial metastatic medulloblastoma in adult patients.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Medulloblastoma / surgery. Neoadjuvant Therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Neuroectodermal Tumors / radiotherapy. Neuroectodermal Tumors / surgery. Remission Induction. Retrospective Studies. Spine / radiation effects. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240913.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Howes TL, Buatti JM, Kirby PA, Carlisle TL, Ryken TC: Radiation induced adult medulloblastoma: a case report. J Neurooncol; 2006 Nov;80(2):191-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation induced adult medulloblastoma: a case report.
  • Adult medulloblastoma is a rare intracranial tumor.
  • Our patient is a 61 year old woman treated with cranial irradiation 15 years previously for a low grade astrocytoma in the left posterior temporal lobe that was recently diagnosed with medulloblastoma in the right cerebellum.
  • This is the first reported case of radiation induced adult medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Medulloblastoma / etiology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710747.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Jouanneau E, Tovar RA, Desuzinges C, Frappaz D, Louis-Tisserand G, Sunyach MP, Jouvet A, Sindou M: Very Late Frontal Relapse of Medulloblastoma Mimicking a Meningioma in an Adult. Neurosurgery; 2006 Apr 01;58(4):E789

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very Late Frontal Relapse of Medulloblastoma Mimicking a Meningioma in an Adult.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28180554.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Pfister SM, Remke M, Benner A, Werft W, Mendrzyk F, Scheurlen W, Kulozik A, Lichter P, Korshunov A: Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma.
  • : 2030 Background: While in children medulloblastoma comprises the most common malignant brain tumor, it accounts for only 1% of intracranial malignancies in adults.
  • The infrequent appearance of MB in adults poses the question, whether these tumors are the same in adults and children in terms of biological and clinical peculiarities.
  • METHODS: Array-CGH was performed for a total 34 adult medulloblastoma samples (>18 years) and results were compared with data from 101 pediatric patients.
  • Selected genomic regions were further investigated by FISH analysis in an independent cohort of 415 samples (112 adult and 303 pediatric).
  • All 146 adult patients received a standard treatment regimen consisting of tumor resection, irradiation of the neuroaxis with 36 Gy, a boost of 20-23 Gy to the posterior fossa, and eight cycles of vincristin, lomustine, and cisplatin.
  • RESULTS: Copy-number gains of chromosome 17q as well as high-level amplifications of CDK6 were identified as significant adverse prognostic markers in adult medulloblastoma.
  • Apart from one exception, CDK6 amplifications were only observed in adult patients (9% in adults versus 0.2 % in children), whereas amplifications of MYC or MYCN were significantly overrepresented in the pediatric cohort, but when present were also associated with dismal prognosis in adults.
  • Based on these results, we propose a molecular staging system for adult medulloblastoma: i) cases with oncogene amplification (10% of cases, 5-year OS = 0%);.
  • CONCLUSIONS: We report on the largest cohort of adult medulloblastoma investigated for genomic imbalances to date.
  • We propose a model for the molecular risk stratification of adult medulloblastoma comprising three distinct genomic risk groups with significantly different survival and tumor biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964634.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Giordana MT, D'Agostino C, Pollo B, Silvani A, Ferracini R, Paiolo A, Ghiglione P, Chiò A: Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):869-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplasia is rare and does not influence prognosis in adult medulloblastoma.
  • Histopathologic grading based on increasing anaplasia predicts clinical behavior of pediatric medulloblastomas.
  • The present study was aimed at grading 86 medulloblastomas of adult patients (aged 18 and older) by anaplasia and analyzing the predictive power.
  • Severe nuclear pleomorphism was found in 4 of 86 cases; the only large-cell medulloblastoma was from an 18-year-old patient.
  • The histologic spectrum of medulloblastoma in adults is different from that in children.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215458.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


17. Menon G, Krishnakumar K, Nair S: Adult medulloblastoma: clinical profile and treatment results of 18 patients. J Clin Neurosci; 2008 Feb;15(2):122-6
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma: clinical profile and treatment results of 18 patients.
  • The objective of this article is to examine the clinicoradiological features and surgical outcomes of adult patients (>16 years) with medulloblastoma.
  • An attempt was made to identify the predictors of poor outcome and assess patterns of relapse and to compare these with pediatric medulloblastoma.
  • Retrospective case record analyses were performed on 18 adults (>16 years) and 79 children (<16 years) operated upon after January 1990, who had at least 5 years of follow-up.
  • The tumor was located in the vermis in 12 patients (66.6%) and in the cerebellar hemisphere in six (16.6%).
  • In spite of recent advances in management, patients with medulloblastoma still have a poor prognosis.
  • However, adults fared better than children.
  • Vermian location had a better outcome in adults, but not in children.
  • Desmoplastic variant histology was not observed to be a significant prognostic factor in the adult group while brain stem invasion carried a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Clinical Trials as Topic. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18078755.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


18. Ang C, Hauerstock D, Guiot MC, Kasymjanova G, Roberge D, Kavan P, Muanza T: Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer; 2008 Nov;51(5):603-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of medulloblastoma in adults.
  • BACKGROUND: Adult medulloblastoma is a rare disease for which there is no internationally accepted standard of care.
  • We sought to review the presentation, management, and outcome of patients with adult medulloblastoma treated at the McGill University teaching hospitals over the past 18 years.
  • METHODS: Medical records were reviewed to gather demographic and clinical data including presenting symptoms, tumor characteristics, management, survival, and treatment toxicity.
  • CONCLUSION: Adult medulloblastoma has distinct characteristics from the pediatric population including presentation in the lateral cerebellar hemispheres.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / therapy. Medulloblastoma / pathology. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neurosurgical Procedures. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18649371.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD: Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol; 2009 Aug;71(2):165-79
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET).
  • Medulloblastoma and supratentorial primitive neuroectodermal tumors are rare diseases in adults.
  • Due to this rarity, few prospective clinical trials have been conducted on medulloblastoma in adults, investigations being based exclusively on retrospective studies; the populations considered in literature are small, and the different treatments given span decades, during which diagnostic procedures, neurosurgical skills and radiotherapy techniques have changed.
  • Unlike pediatric patients, adult medulloblastoma patients have been treated according to risk-adapted therapeutic strategies in only a few series and despite risk-tailored treatments, 20-30% of patients experience recurrence.
  • An important challenge for the future will be the biological characterization of medulloblastoma, with the identification of specific genetic patterns of patients with a better or a worse prognosis.
  • [MeSH-major] Brain Neoplasms. Medulloblastoma. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Child. Female. Genetic Predisposition to Disease. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303318.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 71
  •  go-up   go-down


20. Furtado SV, Venkatesh PK, Dadlani R, Reddy K, Hegde AS: Adult medulloblastoma and the "dural-tail" sign: rare mimic of a posterior petrous meningioma. Clin Neurol Neurosurg; 2009 Jul;111(6):540-3
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma and the "dural-tail" sign: rare mimic of a posterior petrous meningioma.
  • The histological diagnosis was classical medulloblastoma.
  • We review literature of this atypical presentation of medulloblastoma and "dural-tail" sign, which can be associated with other benign or malignant lesions.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Dura Mater / pathology. Infratentorial Neoplasms / pathology. Medulloblastoma / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Spectroscopy. Male. Petrous Bone. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285790.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 19
  •  go-up   go-down


21. Yong RL, Kavanagh EC, Fenton D, Dorovini-Zis K, Heran MK, Haw CS: Midline cerebellar medulloblastoma in a seventy-one-year-old patient. Can J Neurol Sci; 2006 Feb;33(1):101-4
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midline cerebellar medulloblastoma in a seventy-one-year-old patient.
  • BACKGROUND: Medulloblastoma is the most common malignant central nervous system tumour in children but, in contrast, quite rare in adults.
  • Hemispheric, rather than midline, cerebellar medulloblastomas are more common in older children and adults.
  • We present the unusual case of a 71-year-old man who presented with a fourth ventricular mass that proved to be a medulloblastoma.
  • A CT scan of the brain revealed a hyperattenuating, partially calcified, avidly enhancing mass within the fourth ventricle.
  • These findings were consistent with a classical medulloblastoma.
  • CONCLUSION: Adult medulloblastoma should be considered in the differential diagnosis of a partially calcified hyperattenuating mass within the fourth ventricle.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / pathology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Fourth Ventricle / pathology. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583731.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


22. Chargari C, Feuvret L, Levy A, Lamproglou I, Assouline A, Hemery C, Ghorbal L, Lopez S, Tep B, G GB, Lang P, Laigle-Donadey F, Cornu P, Mazeron JJ, Simon JM: Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. Br J Neurosurg; 2010 Aug;24(4):460-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse.
  • BACKGROUND: Clinical outcome and prognostic factors were assessed in adult medulloblastoma patients, with emphasis on patterns of relapse.
  • PATIENTS AND METHODS: Records of 36 consecutive adult patients with medulloblastoma were reviewed.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Humans. Magnetic Resonance Angiography. Male. Middle Aged. Outcome Assessment (Health Care). Prognosis. Radiotherapy, Adjuvant / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726753.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Padovani L, André N, Carrie C, Muracciole X: [Childhood and adult medulloblastoma: what difference?]. Cancer Radiother; 2009 Oct;13(6-7):530-5
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood and adult medulloblastoma: what difference?].
  • [Transliterated title] Le médulloblastome de l'enfant et de l'adulte: quelle différence?
  • Medulloblastoma is the most frequent childhood brain tumor (30%) but account only for less than 1% of adult brain tumor.
  • Due to the rarety in adult population, no prospective studies and few data about late effects are available.
  • Adult medulloblastoma is a therapeutic challenge and their therapeutic strategies are similar to pediatric protocols.
  • In order to improve the understanding of adult disease and to homogenize the treatment, National Cancer Institute (INCa) stimulated the creation of web conference to discuss each case prospectively and to propose a protocol of treatment.
  • A better comprehension of biological processes and abnormal cellular signalling pathways involved in medulloblastoma pathogenesis had led toward a new prognostic classification to adapt the therapeutic strategy and gives hope of new therapeutic tools.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / epidemiology. Child. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Combined Modality Therapy. France / epidemiology. Humans. Incidence. Molecular Biology / methods. Radiotherapy / adverse effects. Radiotherapy / methods. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713143.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Schober R, Kirsten H, Ganten TM, Ahnert P: Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet; 2007 Oct 15;178(2):104-13
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular biological characterization of an adult medulloblastoma.
  • Medulloblastoma is a malignant invasive embryonal tumor, occurring in children mainly.
  • It is rare in adults (<1% of adult brain tumors), and so comprehensive cytogenetic and molecular biological data on adult medulloblastomas are very limited.
  • We performed comprehensive cytogenetic analyses of an adult medulloblastoma, WHO grade IV, using trypsin-Giemsa staining (GTG-banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-specific FISH, complemented by molecular karyotyping using high-density single nucleotide polymorphism (SNP) arrays.
  • Molecular karyotyping by SNP array confirmed chromosomal changes -2p, -10q, -16q, and -Xq and revealed de novo partial uniparental disomy 1q and 9q.
  • Applying an upcoming therapeutic approach, we found that primary medulloblastoma cells were resistant to TRAIL, a novel anticancer cytokine, but could be efficiently sensitized by cotreatment with the proteasome inhibitor bortezomib.
  • Bortezomib-TRAIL cotreatment may serve as a powerful therapeutic option for medulloblastoma patients.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Child. Chromosome Aberrations. Chromosome Banding. Female. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Matrix Metalloproteinase 2 / genetics. Phosphopyruvate Hydratase / genetics. Polymorphism, Single Nucleotide. Synaptophysin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954265.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


25. Selek U, Zorlu F, Hurmuz P, Cengiz M, Turker A, Soylemezoglu F, Gurkaynak M: Craniospinal radiotherapy in adult medulloblastoma. Strahlenther Onkol; 2007 May;183(5):236-40
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniospinal radiotherapy in adult medulloblastoma.
  • PURPOSE: To evaluate the outcome and prognostic factors of adult patients with medulloblastoma.
  • PATIENTS AND METHODS: 26 adult medulloblastoma patients with a median age of 27 were subjected to craniospinal radiotherapy.
  • Patient characteristics, treatment factors and tumor characteristics failed to show any significance in univariate analysis.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Cranial Irradiation. Medulloblastoma / radiotherapy. Spine / radiation effects
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497094.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Poelen J, Bernsen HJ, Prick MJ: Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg; 2007 Jun;107(2):51-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic medulloblastoma in an adult; treatment with temozolomide.
  • Medulloblastoma is a malignant brain tumour most frequently seen in children.
  • Relapses of medulloblastoma are sensitive to chemotherapy and treatment with chemotherapeutics in children has increased the survival rates.
  • A medulloblastoma at adult age is extremely rare, and there is no overall accepted treatment, especially not in the case of a relapse.
  • This observation encouraged us to decide to treat an adult patient with a recurrent medulloblastoma with temozolomide.
  • This female patient showed a recurrence of a medulloblastoma 7 years after the initial presentation with metastatic spread along the neuraxis and progressive neurological deterioration.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710841.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


27. Kochbati L, Bouaouina N, Hentati D, Nasr C, Besbes M, Benna F, Boussen H, Maalej M: [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors]. Cancer Radiother; 2006 May;10(3):107-11
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors].
  • [Transliterated title] Medulloblastoma with extracentral nervous system metastases: clinical presentation and risk factors.
  • PURPOSE: Extra-central nervous system (extra-CNS) metastases are relatively unknown failure patterns in medulloblastoma.
  • The aim of this study was to analyse epidemiological, clinical and aetiopathological aspects of these extra-CNS localisations.
  • PATIENTS AND METHODS: Extra-CNS metastases were retrospectively identified in patients treated in the department of radiation therapy at Salah-Azaïz institute (ISA) for medulloblastoma.
  • These metastases were diagnosed as extra-CNS for all secondary localisations not related to other tumour aetiology.
  • RESULTS: Among 103 patients treated and followed-up in the department of radiation therapy of ISA from 1970 to 1992, 8 developed extra-CNS metastases (7.7%).
  • The mean free-interval from diagnosis of primitive tumour to extra-CNS metastases was 23 months, varying from 8 to 53 months.
  • All patients died or are in progressive disease in less than one year from the diagnosis of extra-CNS metastases.
  • CONCLUSION: Extra-CNS metastases are not rare and have a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / secondary. Nervous System Neoplasms / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600659.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Roussos I, Balaña C, Cuadras P, Ballester R, Etxaniz O, Hostalot C: Medulloblastoma in young adults. Must we give adjuvant chemotherapy? Clin Transl Oncol; 2007 Feb;9(2):121-3
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma in young adults. Must we give adjuvant chemotherapy?
  • Medulloblastoma is a rare entity in adult patients.
  • Reports of medulloblastoma in adults are scarce but in all of them the prognosis seems similar to the prognosis of children.
  • We present our experience in five cases of medulloblastoma in young adults, treated at the University Hospital "Germans Trias i Pujol" from June 1994 to October 2003.
  • We have reviewed the literature, concluding that we have to adapt the findings in children to our adult patients, offering them adjuvant chemotherapy after surgery.
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329226.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Dagostino C, Clara E, Chio A, Giordana MT: Morphophenotype of medulloblastoma in children and adults. The size of nuclei. Clin Neuropathol; 2006 Sep-Oct;25(5):227-31
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphophenotype of medulloblastoma in children and adults. The size of nuclei.
  • OBJECTIVE: Uniform cells with round, regular nuclei characterize the typical histologic aspect of medulloblastoma.
  • Enlargement of nuclei distinguishes the large-cell medulloblastoma variant and is associated with a poor prognosis in pediatric medulloblastomas.
  • The aim of the present study was to compare the size of nuclei between pediatric and adult medulloblastomas by a morphometric analysis.
  • MATERIAL AND METHODS: In 79 neurosurgical specimens of cerebellar medulloblastomas, the maximum nuclear diameter of the largest nuclei was measured.
  • Measurements were performed with a digital-image analysis system.
  • RESULTS: The difference between the mean values in children and adults was statistically significant (p = 0,001).
  • The distribution of maximum values measured in each case had two distinct peaks in the two age groups, in 3.5% of adult cases and in more than 30% of pediatric cases the maximum nuclear size was superior to 12 microm.
  • CONCLUSIONS: The present results show that nuclei of tumor cells in pediatric medulloblastomas are larger than those in adult medulloblastomas and confirm that the phenotype of medulloblastoma is different in the two age groups.
  • Distinct genetic events can, thus, underlie medulloblastoma in childhood and adult age, the prognostic role of genetic variables can differ by age.
  • [MeSH-major] Cell Nucleus / ultrastructure. Cerebellar Neoplasms / ultrastructure. Medulloblastoma / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Image Processing, Computer-Assisted. Infant. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007445.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


30. Ongürü O, Karslioglu Y, Ozcan A, Celik E: Anti-apoptotic and growth-promoting markers in adult medulloblastomas. Clin Neuropathol; 2010 Nov-Dec;29(6):384-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-apoptotic and growth-promoting markers in adult medulloblastomas.
  • AIM: the aim of this study was to investigate the pathologic features, proliferation potential and expression of some anti-apoptotic and growth-promoting markers in adult medulloblastomas.
  • METHOD: we analyzed the immunohistochemical expression of survivin, c-KIT, Bcl-2, fascin, p-53 and Ki-67 in 18 adult medulloblastomas (> 16 years of age).
  • 14 cases were classical, 2 desmoplastic/nodular and 2 large cell medulloblastomas.
  • Moderate-to-high nuclear survivin expression was observed with high percentages (55 - 100%) in all medulloblastomas while Bcl-2 was mildly positive in only 1 case.
  • Fascin expression was observed in 13 medulloblastomas (72%), 9 of which showing moderate to high immunoreactivity.
  • CONCLUSION: frequent nuclear survivin expression implies the predominance of anti-apoptotic factors in pathogenesis of adult medulloblastomas.
  • It may also be a potential therapeutic target for adult medulloblastomas.
  • Although Blc-2 immunoreactivity was previously reported in approximately 30% in medulloblastomas, we have observed that it is rarely expressed in the present series of adult medulloblastomas.
  • To our knowledge, this is the first study evaluating fascin expression in medulloblastomas.
  • Mild-to-moderate cytoplasmic c-KIT immunoreactivity without membranous staining in adult medulloblastomas may support the previous studies reporting low level of c-KIT protein expression with lack of activating mutations in medulloblastomas.
  • It seems p53 is rarely involved in the course of develepment of adult medulloblastomas.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Cerebellar Neoplasms / metabolism. Growth Substances / metabolism. Medulloblastoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Microfilament Proteins / metabolism. Microtubule-Associated Proteins / metabolism. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073843.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Growth Substances; 0 / Inhibitor of Apoptosis Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 146808-54-0 / fascin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


31. Padovani L, Sunyach MP, Perol D, Mercier C, Alapetite C, Haie-Meder C, Hoffstetter S, Muracciole X, Kerr C, Wagner JP, Lagrange JL, Maire JP, Cowen D, Frappaz D, Carrie C: Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys; 2007 Jun 1;68(2):433-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults.
  • PURPOSE: To assess prognostic factors for adults with medulloblastoma in a multicenter, retrospective study.
  • METHODS AND MATERIALS: Data were collected by file review or mail inquiry for 253 adults treated between 1975 to 2004.
  • CONCLUSION: We report the largest series of medulloblastoma in adults.
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498567.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


32. Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G, Pignoli E, Poggi G, Terenziani M, Pedrazzoli P, Siena S, Fossati-Bellani F: Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer; 2005 Jun;41(9):1304-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of adults treated for medulloblastoma using paediatric protocols.
  • We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols.
  • Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Chemotherapy, Adjuvant / methods. Cranial Irradiation / methods. Disease-Free Survival. Humans. Infusions, Intravenous. Lomustine / administration & dosage. Lomustine / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / mortality. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869875.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


33. Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M: Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer; 2007 Nov 1;110(9):2035-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a prospective study on the treatment of medulloblastoma in adults.
  • BACKGROUND: Because medulloblastoma (MB) is rare in adults, the few studies on this condition have been retrospective, and the follow-up has tended to be short.
  • METHODS: In 1989, a prospective Phase II trial was initiated to evaluate the efficacy of treatment for adults with MB.
  • Patients were staged completely with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology, according to Chang's staging system.
  • RESULTS: After a median follow up of 7.6 years, among a total of 36 adults with MB, the overall progression-free survival (PFS) and overall survival (OS) rates at 5 years were 72% and 75%, respectively.
  • CONCLUSIONS: In adult patients with MB, long-term follow-up was essential for evaluating the real impact of treatments.
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prospective Studies. Radiotherapy. Survival Rate. Time. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823910.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Razak AR, Nasser Q, Morris P, Alcutt D, Grogan L: Medulloblastoma in two successive pregnancies. J Neurooncol; 2005 May;73(1):89-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma in two successive pregnancies.
  • Magnetic resonance imaging brain showed evidence of a cerebellar vermis lesion.
  • This was diagnosed as medulloblastoma on histopathological analysis.
  • We believe this is the first reported description of recurrent medulloblastoma in successive pregnancies.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Medulloblastoma / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Pregnancy. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933823.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; IVAD protocol
  •  go-up   go-down


35. Pizem J, Cör A, Zadravec Zaletel L, Popovic M: Prognostic significance of apoptosis in medulloblastoma. Neurosci Lett; 2005 Jun 10-17;381(1-2):69-73
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of apoptosis in medulloblastoma.
  • Since apoptosis is a major contributor to cell loss in medulloblastoma, either spontaneous or induced by radiation and chemotherapy, the apoptotic rate in resection specimens could have prognostic significance.
  • We analysed the apoptotic rate in 58 medulloblastoma resection specimens using an antibody against cleaved caspase 3, a specific marker of apoptotic cell death, and tested its possible prognostic significance.
  • The apoptotic rate varied considerably among medulloblastomas (0.1-25.9%, median 1.1%).
  • The apoptotic rate was higher in medulloblastomas with CSF dissemination, tended to be higher in desmoplastic medulloblastomas, but there was no association with age group and sex.
  • The variation in apoptotic rate among medulloblastomas is very likely predominantly associated with variations in tumour microenvironment, as supported by apoptotic cell clustering and rimming around necrotic areas.
  • The apoptotic rate in medulloblastoma resection specimens does not seem to be of prognostic value.
  • [MeSH-major] Apoptosis. Cerebellar Neoplasms / classification. Cerebellar Neoplasms / pathology. Medulloblastoma / classification. Medulloblastoma / pathology. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882792.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


36. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A: MicroRNA profiling in human medulloblastoma. Int J Cancer; 2009 Feb 1;124(3):568-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling in human medulloblastoma.
  • Medulloblastoma is an aggressive brain malignancy with high incidence in childhood.
  • However, no data are yet available on human primary medulloblastomas.
  • A high throughput microRNA expression profiles was performed in human primary medulloblastoma specimens to investigate microRNA involvement in medulloblastoma carcinogenesis.
  • We identified specific microRNA expression patterns which distinguish medulloblastoma differing in histotypes (anaplastic, classic and desmoplastic), in molecular features (ErbB2 or c-Myc overexpressing tumors) and in disease-risk stratification.
  • MicroRNAs expression profile clearly differentiates medulloblastoma from either adult or fetal normal cerebellar tissues.
  • Only a few microRNAs displayed upregulated expression, while most of them were downregulated in tumor samples, suggesting a tumor growth-inhibitory function.
  • This property has been addressed for miR-9 and miR-125a, whose rescued expression promoted medulloblastoma cell growth arrest and apoptosis while targeting the proproliferative truncated TrkC isoform.
  • In conclusion, misregulated microRNA expression profiles characterize human medulloblastomas, and may provide potential targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cerebellar Neoplasms / genetics. Gene Expression Profiling. Medulloblastoma / genetics. MicroRNAs

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973228.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP07118
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


37. Yoshimura J, Nishiyama K, Fukuda M, Watanabe M, Igarashi H, Fujii Y: Adult cerebellopontine angle medulloblastoma originating in the pons mimicking focal brainstem tumor. J Neuroimaging; 2009 Oct;19(4):385-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult cerebellopontine angle medulloblastoma originating in the pons mimicking focal brainstem tumor.
  • We herein report a rare case of cerebellopontine angle (CPA) medulloblastoma originating in the brainstem that demonstrated a very unusual clinical presentation and radiological appearances.
  • A small non-enhanced lesion having minimal mass effect in the right CPA was identified by using a 1.5-tesla-MR system, whose size remained almost unchanged a year.
  • MR spectroscopic images using a 3-tesla system revealed a high ratio of choline-to-N-acetylaspartate in the region of interest in comparison to the contra-lateral side.
  • The histopathological diagnosis was medulloblastoma.
  • MR spectroscopic imaging is considered to be quite useful for the management of this rare type of brainstem tumor.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Cerebellopontine Angle / pathology. Infratentorial Neoplasms / pathology. Medulloblastoma / pathology. Pons / pathology
  • [MeSH-minor] Adult. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Choline / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Functional Laterality. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021841.001).
  • [ISSN] 1552-6569
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline
  •  go-up   go-down


38. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ: Subtypes of medulloblastoma have distinct developmental origins. Nature; 2010 Dec 23;468(7327):1095-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of medulloblastoma have distinct developmental origins.
  • Medulloblastoma encompasses a collection of clinically and molecularly diverse tumour subtypes that together comprise the most common malignant childhood brain tumour.
  • The pathological processes that drive heterogeneity among the other medulloblastoma subtypes are not known, hindering the development of much needed new therapies.
  • Here we provide evidence that a discrete subtype of medulloblastoma that contains activating mutations in the WNT pathway effector CTNNB1 (hereafter, WNT subtype) arises outside the cerebellum from cells of the dorsal brainstem.
  • We found that genes marking human WNT-subtype medulloblastomas are more frequently expressed in the lower rhombic lip (LRL) and embryonic dorsal brainstem than in the upper rhombic lip (URL) and developing cerebellum.
  • These lesions persisted in all mutant adult mice; moreover, in 15% of cases in which Tp53 was concurrently deleted, they progressed to form medulloblastomas that recapitulated the anatomy and gene expression profiles of human WNT-subtype medulloblastoma.
  • We provide the first evidence, to our knowledge, that subtypes of medulloblastoma have distinct cellular origins.
  • Our data provide an explanation for the marked molecular and clinical differences between SHH- and WNT-subtype medulloblastomas and have profound implications for future research and treatment of this important childhood cancer.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] Curr Opin Cell Biol. 2009 Dec;21(6):741-7 [19883998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 4;107(18):8422-7 [20400693.001]
  • [Cites] Nature. 2010 Jul 29;466(7306):632-6 [20639864.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] Hum Mol Genet. 2001 Jun 1;10(12):1325-34 [11406614.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5428-37 [14500378.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Development. 2005 May;132(10):2425-39 [15843415.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • [Cites] Genes Dev. 2005 Nov 15;19(22):2656-67 [16260494.001]
  • [Cites] Neuron. 2005 Dec 22;48(6):933-47 [16364898.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Neuron. 2006 Apr 20;50(2):205-18 [16630833.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] J Neurosci. 2006 Nov 22;26(47):12226-36 [17122047.001]
  • [Cites] Annu Rev Pathol. 2008;3:341-65 [18039127.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):443-57 [18371380.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):123-34 [18691547.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):135-45 [18691548.001]
  • [Cites] PLoS One. 2008;3(8):e3088 [18769486.001]
  • [Cites] Development. 2009 Jan;136(2):295-305 [19088088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1880-5 [19164512.001]
  • [Cites] Neuroscience. 2009 Sep 1;162(3):560-73 [19303920.001]
  • [CommentIn] Nat Rev Cancer. 2011 Feb;11(2):79 [21322837.001]
  • [CommentIn] Nat Rev Cancer. 2011 Feb;11(2):80 [21436788.001]
  • (PMID = 21150899.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE24628
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541-04; United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / R01CA129541; United States / NINDS NIH HHS / NS / R01 NS037956; United States / NCI NIH HHS / CA / R01 CA129541-02; United States / NCI NIH HHS / CA / R01 CA129541-05; United States / NCI NIH HHS / CA / R01 CA129541-03; United States / NCI NIH HHS / CA / P30CA021765; United States / NCI NIH HHS / CA / 01CA96832; United States / NCI NIH HHS / CA / P01 CA096832-06A18120; United States / NCI NIH HHS / CA / CA096832-078120; United States / NCI NIH HHS / CA / R01 CA129541-01; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA096832; United States / NINDS NIH HHS / NS / R01 NS037956-13; United States / NCI NIH HHS / CA / CA096832-06A18120; United States / NCI NIH HHS / CA / P01 CA096832-078120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS245937; NLM/ PMC3059767
  •  go-up   go-down


39. Yoshimura J, Nishiyama K, Mori H, Takahashi H, Fujii Y: Intrathecal chemotherapy for refractory disseminated medulloblastoma. Childs Nerv Syst; 2008 May;24(5):581-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrathecal chemotherapy for refractory disseminated medulloblastoma.
  • OBJECTIVE: To analyze the effect of intrathecal (IT) chemotherapy for disseminated medulloblastoma.
  • CONCLUSION: IT chemotherapy was found to be effective in some cases with refractory disseminated medulloblastoma and it seems to be an appropriate treatment choice for leptomeningeal recurrence.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Immunosuppressive Agents / therapeutic use. Medulloblastoma / therapy. Methotrexate / therapeutic use. Nitrosourea Compounds / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy / methods. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / prevention & control. Nimustine / therapeutic use. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057943.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Nitrosourea Compounds; 0S726V972K / Nimustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Sousa R, Sá G, Reimão S, Lopes L, Ruivo J, Albuquerque L, Campos J: [Adult cerebellar medulloblastoma: imaging findings in eight cases]. Acta Med Port; 2006 Nov-Dec;19(6):466-70
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult cerebellar medulloblastoma: imaging findings in eight cases].
  • Medulloblastoma is a brain tumor of neuroepithelial origin, frequent in children but rare in adults.
  • The imaging pattern is well studied in the pediatric group thought there is controversy about the imaging characteristics in adults.
  • We report CT and MRI imaging findings of 8 adult patients with cerebellar medulloblastoma.
  • The imaging findings of medulloblastomas in adults are unspecific and different from those in child.
  • They should be considered in the differential diagnosis of cerebellar tumor in adults, especially if they are hyperdense on CT, with well defined margins, with superficial extension and with dural involvement.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Medulloblastoma / pathology. Medulloblastoma / radiography
  • [MeSH-minor] Adolescent. Adult. Cerebellum / pathology. Cerebellum / radiography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583605.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


41. Teider N, Scott DK, Neiss A, Weeraratne SD, Amani VM, Wang Y, Marquez VE, Cho YJ, Pomeroy SL: Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol; 2010 Dec;12(12):1244-56
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma.
  • Human Neuralized1 (NEURL1) was investigated as a potential tumor suppressor in medulloblastoma (MB).
  • NEURL1-transfected MB cell lines demonstrated decreased population growth, colony-forming ability, tumor sphere formation, and xenograft growth compared with controls, and a significant increase in apoptosis was seen on cell cycle and cell death analysis.
  • From these studies, we conclude that NEURL1 is a candidate tumor suppressor in MB, at least in part through its effects on the Notch pathway.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comp Neurol. 2001 Jul 23;436(2):167-81 [11438922.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7481-94 [11585928.001]
  • [Cites] Curr Biol. 2001 Oct 30;11(21):1675-9 [11696324.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Mol Cell Neurosci. 2002 Aug;20(4):649-68 [12213446.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6456-61 [12438235.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8771-9 [12496248.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Dev Biol. 2003 Nov 1;263(1):50-66 [14568546.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):756-67 [14570040.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):661-8 [14688019.001]
  • [Cites] Lab Invest. 1991 Jun;64(6):833-43 [1904513.001]
  • [Cites] Oncol Res. 1995;7(10-11):493-503 [8866661.001]
  • [Cites] Trends Cell Biol. 2000 Oct;10(10):429-39 [10998601.001]
  • [Cites] Oncogene. 1998 Feb 26;16(8):1009-19 [9519875.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7794-800 [15520185.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10256-62 [15542835.001]
  • [Cites] Development. 2005 Apr;132(8):1751-62 [15790962.001]
  • [Cites] Development. 2005 Aug;132(15):3459-70 [16000382.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):47-60 [16149064.001]
  • [Cites] Genes Dev. 2006 Jan 15;20(2):236-52 [16418486.001]
  • [Cites] Dev Neurosci. 2006;28(1-2):70-80 [16508305.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1123-36 [16618801.001]
  • [Cites] Nature. 2006 May 18;441(7091):349-53 [16625203.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Oncogene. 2006 Aug 31;25(39):5446-61 [16607277.001]
  • [Cites] Chem Senses. 2006 Oct;31(8):725-30 [16855061.001]
  • [Cites] Oncogene. 2006 Nov 9;25(53):7059-69 [16715130.001]
  • [Cites] Cell Cycle. 2006 Oct;5(20):2381-9 [17102621.001]
  • [Cites] Mol Biol Cell. 2007 Jan;18(1):1-13 [17065551.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):77-90 [16799634.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):52-9 [17178457.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2215-25 [17371797.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):384-90 [17708532.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] APMIS. 2007 Dec;115(12):1357-63 [18184405.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3846-53 [18077452.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):201-7 [18291635.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):741-50 [18488029.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):529-41 [18538736.001]
  • [Cites] PLoS One. 2008;3(8):e3088 [18769486.001]
  • [Cites] BMC Cancer. 2008;8:280 [18826648.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9907-12 [11481456.001]
  • (PMID = 20847082.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / P30 HD018655; United States / NCI NIH HHS / CA / R01CA109467; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / HEY1 protein, human; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins; 149348-15-2 / HES1 protein, human; EC 6.3.2.19 / NEURL1 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Other-IDs] NLM/ PMC3018940
  •  go-up   go-down


42. Xu P, Pu PY, Kang CS, Jia ZF, Zhou X, Wang GX: [Differential expression of Notch1 and Notch2 in astrocytoma and medulloblastoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Jul;37(7):450-3
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential expression of Notch1 and Notch2 in astrocytoma and medulloblastoma].
  • OBJECTIVE: To detect the differential expression of Notch1 and Notch2 in human astrocytoma and medulloblastoma; and to study the role of Notch1 and Notch2 in the development of both tumors.
  • METHODS: Immunohistochemical staining (SP method) and Western blot analysis were used to detect Notch1 and Notch2 expression in tissue arrays and freshly resected samples of normal brain tissue, astrocytoma and medulloblastoma.
  • RESULTS: Notch1 and Notch2 were negative in normal human brain tissue.
  • The percentage of positive tumor cells and expression level of Notch1 increased with higher histologic grade (r = 0.859, P < 0.05).
  • On the other hand, overexpression of Notch2 was detected in medulloblastoma (9/10) in contrast with lower expression of Notch1 (2/10).
  • CONCLUSIONS: Notch1 and Notch2 show differential expression in astrocytoma and medulloblastoma.
  • This may be related to their different functional activities during the process of brain development.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Medulloblastoma / metabolism. Receptor, Notch1 / metabolism. Receptor, Notch2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Brain Neoplasms / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035115.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Notch1; 0 / Receptor, Notch2
  •  go-up   go-down


43. Spiller SE, Ravanpay AC, Hahn AW, Olson JM: Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol; 2006 Sep;79(3):259-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
  • PURPOSE: Suberoylanilide hydroxamic acid (SAHA) has been studied in adult solid and hematologic malignancies.
  • However, little information has been reported on the effects of SAHA on central nervous system (CNS) tumors including medulloblastoma, the most common malignant brain tumor in children.
  • We investigated SAHA in preclinical medulloblastoma models to determine its anti-cancer efficacy as well as its ability to affect intracranial lesions when administered systemically.
  • EXPERIMENTAL DESIGN AND RESULTS: Tissue culture studies were performed treating primary human fibroblasts, established medulloblastoma cell lines, and primary human medulloblastoma tumors with SAHA.
  • At 10 microM concentration, SAHA had little effect on normal fibroblasts but caused >90% apoptosis in cultured medulloblastoma cells.
  • Primary medulloblastomas from patients were sensitive to SAHA compared to vehicle alone in ex vivo studies.
  • In athymic mice with medulloblastoma xenograft tumors, oral SAHA resulted in apoptosis of tumor tissue and significantly slowed tumor growth.
  • In the ND2:Smo transgenic mouse medulloblastoma model, SAHA treatment caused significant apoptosis in these cerebellar tumors.
  • CONCLUSIONS: SAHA effectively induces cell death in established medulloblastoma cell lines, human patient primary tumor cultures, medulloblastoma xenografts and intracranial spontaneous medulloblastomas.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cerebellar Neoplasms / drug therapy. Hydroxamic Acids / pharmacology. Medulloblastoma / drug therapy

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645722.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112350-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


44. Barai S, Bandopadhayaya GP, Julka PK, Kale SS, Kumar R, Malhotra A, Haloi AK, Seith A, Naik KK, Dhanapathi H: Evaluation of Tc99m-glucoheptonate for SPECT functional imaging of medulloblastoma. J Clin Neurosci; 2005 Jan;12(1):36-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Tc99m-glucoheptonate for SPECT functional imaging of medulloblastoma.
  • OBJECTIVES: Functional imaging of medulloblastoma using SPECT has been a difficult problem as this tumour does not concentrate conventional brain tumour imaging radiopharmaceuticals.
  • This study aimed to evaluate Tc99m-glucoheptonate as a "brain tumour-seeking" radiopharmaceutical for functional imaging of medulloblastoma.
  • METHODS: Tc99m-glucoheptonate brain SPECT was performed in 27 patients with medulloblastoma after radiation therapy and with clinical suspicion of tumour recurrence.
  • Histopathology confirmed viable medulloblastoma in all cases.
  • CONCLUSION: Tc99m-glucoheptonate is an ideal SPECT tracer for functional evaluation of medulloblastoma.
  • SPECT utilising Tc99m-glucoheptonate is a reliable diagnostic modality to differentiate tumour recurrence from post-radiation gliosis in patients with medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / radionuclide imaging. Medulloblastoma / radionuclide imaging. Organotechnetium Compounds. Radiopharmaceuticals. Sugar Acids
  • [MeSH-minor] Adolescent. Adult. Child. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neurosurgical Procedures. Tomography, Emission-Computed, Single-Photon

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15639408.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / Sugar Acids; I853LE095B / technetium Tc 99m gluceptate
  •  go-up   go-down


45. Wendland MM, Shrieve DC, Watson GA, Chin SS, Blumenthal DT: Extraneural metastatic medulloblastoma in an adult. J Neurooncol; 2006 Jun;78(2):191-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastatic medulloblastoma in an adult.
  • Medulloblastoma is a rare malignancy in adults, accounting for approximately 1% of all primary brain tumors.
  • We report here our experience with a 26 year-old woman with medulloblastoma treated with gross total resection followed by radiation therapy to her craniospinal axis.
  • The treatment of medulloblastoma, particularly salvage therapy following disease recurrence, is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Brain Neoplasms / pathology. Medulloblastoma / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Radiotherapy Dosage. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598430.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Srikantha U, Balasubramaniam A, Santosh V, Somanna S, Bhagavatula ID, Ashwathnarayana CB: Recurrence in medulloblastoma - influence of clinical, histological and immunohistochemical factors. Br J Neurosurg; 2010 Jun;24(3):280-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence in medulloblastoma - influence of clinical, histological and immunohistochemical factors.
  • INTRODUCTION: The therapy for medulloblastomas has gone through several changes over the years.
  • Research has shown that patients with medulloblastoma cannot be satisfactorily stratified into risk groups based on clinical and therapeutic factors alone.
  • AIM: To study the clinical, histological features and expression of immunohistochemical markers in medulloblastoma, and to correlate these features with recurrence rates.
  • MATERIALS AND METHODS: Sixty-three cases of medulloblastomas operated at our institute from 1996-2003 were selected and retrospectively analyzed for therapy received, histological features and immunohistochemical expression of GFAP, synaptophysin, erb B2, p53, Bcl-2 and Trk-C along with assessment of MIB-1 labeling index(LI).
  • CONCLUSION: We propose a clinical-histological-immunohistochemical' model for medulloblastoma where extent of resection, administration of chemotherapy, presence of gross anaplasia and c-erb B2 overexpression status are the most important predictors of recurrence rates.
  • [MeSH-major] Cerebellar Neoplasms. Medulloblastoma. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Female. Humans. Immunohistochemistry. India / epidemiology. Male. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Retrospective Studies. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465457.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


47. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S: Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol; 2008 Oct;116(4):383-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of genomic aberrations during clinical progression of medulloblastoma.
  • Medulloblastomas comprise the most frequent malignant brain tumor in childhood and one of the biggest challenges in pediatric oncology.
  • The current concept suggests that these tumors may undergo stepwise progression as it has been shown for other brain tumors.
  • However, conclusive evidence of molecular progression over time has not been demonstrated yet for medulloblastoma.
  • In the present study, 28 pairs of medulloblastoma at primary diagnosis and at the time of recurrence, either occurring as local tumor regrowth or tumor dissemination, were histopathologically and molecularly analyzed.
  • These results suggest that early recurrence in medulloblastoma mainly occurs in tumors with a highly malignant genotype and phenotype per se, whereas late recurrence is often dependent on tumor evolution toward a more malignant biology.
  • Therefore, biopsy of recurrent tumors should be performed to assess the biologic properties of the relapsed tumor, especially when targeted therapy approaches are considered.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 6 / genetics. Medulloblastoma / genetics. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Cytogenetic Analysis. Disease Progression. Female. Humans. Male. Neoplasm Recurrence, Local / genetics. Prognosis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704466.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


48. Rushing EJ, Smith AB, Smirniotopoulos JG, Douglas AF, Zeng W, Azumi N: Occult leptomeningeal large cell medulloblastoma in an adult. Clin Neuropathol; 2009 May-Jun;28(3):188-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult leptomeningeal large cell medulloblastoma in an adult.
  • OBJECTIVE AND IMPORTANCE: Large cell medulloblastoma is an uncommon malignancy of childhood that often pursues an aggressive clinical course.
  • We report the first case of this entity in an adult that proved to be an unsuspected primary leptomeningeal tumor.
  • Postmortem examination of the brain was notable for necrotic cerebellar tonsils, but demonstrated no evidence of an intraparenchymal mass lesion.
  • Microscopic examination of the cerebellum revealed discohesive neoplastic cells, which showed characteristic dot-like immunoreactivity for synaptophysin, diagnostic of large cell medulloblastoma within the subarachnoid space.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Meningeal Neoplasms / pathology
  • [MeSH-minor] Adult. Arnold-Chiari Malformation / complications. Fatal Outcome. Humans. Intervertebral Disc Displacement / complications. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537136.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret AS, Silva M, Odame I, Mpofu C, Strother D, Wilson B, Samson Y, Bouffet E, Canadian Pediatric Brain Tumor Consortium: Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys; 2006 Feb 1;64(2):402-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma.
  • PURPOSE: To report the clinical course of adolescents with medulloblastoma, with specific emphasis on prognosis and pattern of relapse.
  • METHODS AND MATERIALS: We retrospectively studied the clinical course and outcomes of children aged 10-20 years with medulloblastoma, treated at centers throughout Canada between 1986 and 2003.
  • CONCLUSIONS: Our study suggests that adolescents with medulloblastoma might have a unique prognosis and pattern of relapse, dissimilar to those in younger children.
  • [MeSH-major] Cerebellar Neoplasms / mortality. Medulloblastoma / mortality. Neoplasm Recurrence, Local / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Analysis of Variance. Child. Disease-Free Survival. Female. Humans. Male. Prognosis. Recurrence. Retrospective Studies. Sex Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198067.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


50. McCabe MG, Ichimura K, Pearson DM, Liu L, Clifford SC, Ellison DW, Collins VP: Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosomes Cancer; 2009 Feb;48(2):121-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint.
  • Isodicentric 17q is the most commonly reported chromosomal abnormality in medulloblastomas.
  • Its frequency suggests that genes disrupted in medulloblastoma formation may play a role in tumorigenesis.
  • CGH with a custom tiling path genomic BAC array of chromosome 17 enriched with fosmids at the breakpoint regions was used to analyze a series of 45 medulloblastomas and three medulloblastoma-derived cell lines.
  • In total, 17 of 45 medulloblastomas had an isodicentric 17q.
  • [MeSH-major] Chromosome Breakage. Chromosomes, Human, Pair 17 / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Mapping. Comparative Genomic Hybridization. Female. Gene Deletion. Gene Dosage. Gene Duplication. Humans. Male. Oligonucleotide Array Sequence Analysis. Recombination, Genetic

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973140.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Ciaccio M, Gil S, Guercio G, Vaiani E, Alderete D, Palladino M, Warman DM, Rivarola MA, Belgorosky A: Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma. Horm Res Paediatr; 2010;73(4):281-6
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma.
  • BACKGROUND: GH deficiency (GHD) and spine irradiation (SI) have been implicated in the mechanism of reduced adult height (AH) in childhood survivors of medulloblastoma.
  • However, growth dynamics after tumor diagnosis and the effectiveness of rhGH on AH in comparison with rhGH-untreated survivors have not been reported.
  • AIM: To follow height (H) SDS (HSDS) since tumor diagnosis and the effect of rhGH in GHD patients, comparing with GH-untreated GHD patients.
  • METHODS: 14 patients received rhGH treatment until AH (medulloblastoma GH-treated group, MGHGr).
  • 19 patients refused rhGH therapy (GH-untreated control medulloblastoma group, MCGr).
  • RESULTS: In MGHGr, mean +/- SD HSDS decreased from 0.09 +/- 0.63 at tumor diagnosis to -1.38 +/- 0.91 at diagnosis of GHD, and to -1.90 +/- 0.72 at the onset of rhGH, p < 0.01, but it remained unchanged during rhGH (AH -2.12 +/- 0.55).
  • MCGr HSDS (-0.25 +/- 0.88) was not different from MGHGr at tumor diagnosis, but it was -3.40 +/- 0.88 at AH, significantly lower than in MGHGr, p = 0.001.
  • CONCLUSIONS: rhGH treatment improves AH in GH-deficient childhood medulloblastoma survivors but not spinal growth.
  • [MeSH-major] Body Height / drug effects. Human Growth Hormone / administration & dosage. Human Growth Hormone / deficiency. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adult. Anthropometry. Cohort Studies. Female. Humans. Male. Recombinant Proteins / administration & dosage. Regression Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20215775.001).
  • [ISSN] 1663-2826
  • [Journal-full-title] Hormone research in pædiatrics
  • [ISO-abbreviation] Horm Res Paediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


52. García Casales Z, Echebarría Barona A, Urberuaga Pascual A, Astigarraga Aguirre I, Burgos Bretones JJ, Navajas Gutiérrez A: [Differential aspects in children and adult patients with medulloblastoma]. Med Clin (Barc); 2009 Oct 3;133(12):454-9
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential aspects in children and adult patients with medulloblastoma].
  • [Transliterated title] Meduloblastoma: aspectos diferenciales entre el tumor infantil y del adulto.
  • BACKGROUND AND OBJECTIVE: Medulloblastoma is the more frequent malignant cerebral tumor in childhood.
  • PATIENTS AND METHODS: This is an observational study of a retrospective cohort in which there were included all the patients diagnosed of medulloblastoma in the last 19 years (1989-2007) in Hospital de Cruces of Baracaldo, Vizcaya, Spain.
  • Tumor site and mortality according to initial dissemination were variables of statistic significance.
  • It is important to emphasize the aggressiveness of medulloblastoma in both children and adults, with a global mortality of 56.8% and 48,6% at 5 years.
  • [MeSH-major] Cerebellar Neoplasms. Medulloblastoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Cohort Studies. Confidence Intervals. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Metastasis. Normal Distribution. Retrospective Studies. Spain / epidemiology. Statistics, Nonparametric. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19674760.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


53. Brugières L, Pierron G, Chompret A, Paillerets BB, Di Rocco F, Varlet P, Pierre-Kahn A, Caron O, Grill J, Delattre O: Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. J Med Genet; 2010 Feb;47(2):142-4
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations.
  • METHODS AND RESULTS: Germline SUFU mutations were identified in two families with several children under 3 years of age diagnosed with medulloblastoma.
  • All medulloblastomas in which the histology was reviewed were of the desmoplastic subtype, including three with the rare extensive nodularity subtype.
  • Among the 25 mutation carriers identified in the two families, seven developed medulloblastomas.
  • These are mainly medulloblastomas with extensive nodularity or typical desmoplastic/nodular medulloblastomas.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Germ-Line Mutation. Medulloblastoma / genetics. Penetrance. Repressor Proteins / genetics
  • [MeSH-minor] Adult. Child, Preschool. DNA Mutational Analysis. Family. Female. Genetic Predisposition to Disease. Humans. Infant. Male. Pedigree

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833601.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / SUFU protein, human
  •  go-up   go-down


54. Gandola L, Massimino M, Cefalo G, Solero C, Spreafico F, Pecori E, Riva D, Collini P, Pignoli E, Giangaspero F, Luksch R, Berretta S, Poggi G, Biassoni V, Ferrari A, Pollo B, Favre C, Sardi I, Terenziani M, Fossati-Bellani F: Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol; 2009 Feb 1;27(4):566-71
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.
  • PURPOSE: With a view to improving the prognosis for patients with metastatic medulloblastoma, we tested the efficacy and toxicity of a hyperfractionated accelerated radiotherapy (HART) regimen delivered after intensive sequential chemotherapy.
  • CONCLUSION: HART after intensive postoperative chemotherapy, followed by myeloablative chemotherapy in selected cases, proved feasible in children with metastatic medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose Fractionation. Etoposide / administration & dosage. Female. Humans. Male. Methotrexate / administration & dosage. Neoplasm Metastasis. Radiotherapy Dosage. Survival Rate. Treatment Outcome


55. Viana-Pereira M, Almeida I, Sousa S, Mahler-Araújo B, Seruca R, Pimentel J, Reis RM: Analysis of microsatellite instability in medulloblastoma. Neuro Oncol; 2009 Oct;11(5):458-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of microsatellite instability in medulloblastoma.
  • Medulloblastoma is the most common malignant brain tumor in children.
  • The presence of microsatellite instability (MSI) in brain tumors, particularly medulloblastomas, has not been properly addressed.
  • The aim of the present study was to evaluate the role of MSI in medulloblastoma carcinogenesis.
  • This study is the most comprehensive analysis of MSI in medulloblastomas to date.
  • We observed the presence of MSI together with mutations of MSI target genes in a small fraction of cases, suggesting a new genetic pathway for a role in medulloblastoma development.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Microsatellite Instability
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. DNA Methylation. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Genet. 2002 Apr-Jun;45(2):71-5 [12119215.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4863-71 [12101426.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5738-44 [14522894.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2199-206 [14601090.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):209-18 [15050952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):2023-7 [6759487.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):152-6 [8162069.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5545-7 [7585631.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):56-9 [7497444.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):896-9 [9500446.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1415-9 [9626457.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Oncol Res. 1998;10(8):421-8 [10100759.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2995-3002 [10383166.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4213-5 [10485457.001]
  • [Cites] Dis Markers. 2004;20(4-5):251-7 [15528790.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Feb;131(2):87-93 [15672285.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Ann Hematol. 2005 Jun;84(6):368-75 [15789228.001]
  • [Cites] Nucleic Acids Res. 2005;33(14):e128 [16106041.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):241-51 [16330668.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2113-8 [16288216.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):951-5 [16490738.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):238-43 [16639607.001]
  • [Cites] Cancer Biomark. 2006;2(1-2):69-86 [17192061.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):660-6 [17285135.001]
  • [Cites] Brain Pathol. 2007 Apr;17(2):146-50 [17388945.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2349-56 [17440981.001]
  • [Cites] Eur J Hum Genet. 2007 Sep;15(9):922-9 [17534377.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Oct;133(10):749-59 [17530287.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5919-26 [17384679.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):1055-65 [17700563.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1061-8 [17879369.001]
  • [Cites] DNA Repair (Amst). 2008 Feb 1;7(2):321-8 [18162445.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):971-6 [18281528.001]
  • [Cites] Neuropathol Appl Neurobiol. 2008 Oct;34(5):547-54 [18053027.001]
  • [Cites] Cancer Sci. 2006 Mar;97(3):226-34 [16542220.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):266-8 [10545939.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Trends Cell Biol. 1999 Dec;9(12):M57-60 [10611684.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):433-7 [10666372.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1564-71 [10734316.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):39-48 [11213834.001]
  • [Cites] J Cell Physiol. 2001 May;187(2):137-44 [11267993.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):138-43 [11801550.001]
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • (PMID = 19179424.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2765336
  •  go-up   go-down


56. Mazloom A, Zangeneh AH, Paulino AC: Prognostic factors after extraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys; 2010 Sep 1;78(1):72-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors after extraneural metastasis of medulloblastoma.
  • PURPOSE: To review the existing literature regarding the characteristics, prognostic factors, treatment, and survival of patients with medulloblastoma, who develop extraneural metastasis (ENM).
  • Factors analyzed included age, time interval to development of ENM, ENM location, central nervous system (CNS) involvement, treatment, and outcome.
  • For patients without CNS involvement at the time of ENM diagnosis, the 1-, 2-, and 5-year OS rates for those treated with and without radiotherapy (RT) were 82.4%, 64.8%, and 64.8% vs. 51.0%, 36.6%, and 30.5%, respectively (p = 0.03, log-rank test).
  • RT did not significantly improve OS or PFS rates for those with CNS involvement.
  • Concurrent CNS involvement, ENM in the lung or liver, a time interval of <18 months to development of ENM, and a patient age of <16 years at ENM diagnosis were found to be negative prognostic factors for both OS and PFS.
  • CONCLUSIONS: Several prognostic factors were identified for patients with ENM from medulloblastoma.
  • Patients without concurrent CNS involvement, who received RT after ENM diagnosis had an OS and PFS benefit compared to those who did not receive RT.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Neoplasms / mortality. Bone Marrow Neoplasms / secondary. Bone Marrow Neoplasms / therapy. Bone Neoplasms / mortality. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Infant. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20133080.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


57. Zawlik I, Zakrzewska M, Witusik M, Golanska E, Kulczycka-Wojdala D, Szybka M, Piaskowski S, Wozniak K, Zakrzewski K, Papierz W, Liberski PP, Rieske P: KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural stem cells. Cancer Genet Cytogenet; 2006 Oct 1;170(1):24-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KCTD11 expression in medulloblastoma is lower than in adult cerebellum and higher than in neural stem cells.
  • Medulloblastoma (MB) is the most common malignant brain tumor of childhood, and the most frequent associated genetic alteration is loss of heterozygosity on chromosome region 7p13.
  • We used real-time polymerase chain reaction in 20 tissue samples of primary MB to examine the transcriptional level of the two genes, with reference to two types of controls: adult cerebellum and fetal neural stem cells.
  • A significant reduction of KCTD11 expression relative to adult normal cerebellum was detected in 14 of 20 (70%) of MB samples.
  • HIC1 gene expression was low ( approximately 100 times lower than KCTD11 expression) in MB, and low also in both adult cerebellum and neural stem cells.
  • Hypermethylation of the 5'UTR or the central region of HIC1 (or both) was detected in a significant number of MB samples, as well as in cerebellum and neural stem cells.
  • Our data suggest that KCTD11 may play an important role in MB tumorigenesis, but do not support the role of HIC1 in this tumor development.
  • [MeSH-major] Cerebellum / metabolism. Medulloblastoma / genetics. Nervous System / metabolism. Potassium Channels / genetics. Stem Cells / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965951.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / KCTD11 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Potassium Channels; 0 / Transcription Factors
  •  go-up   go-down


58. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol; 2006 Apr 20;24(12):1924-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
  • MATERIALS AND METHODS: Gene expression profiles of 46 samples of medulloblastoma were generated using the U133av2 Affymetrix oligonucleotide array and validated using real-time reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemistry.
  • RESULTS: Unsupervised analysis of gene expression profiles partitioned medulloblastomas into five distinct subgroups (subgroups A to E).
  • Real-time RT-PCR analysis of gene expression profiles was then used to predict accurately the presence of mutations in the WNT and SHH pathways in a separate group of 31 medulloblastomas.
  • CONCLUSION: Genome-wide expression profiles can partition large tumor cohorts into subgroups that are enriched for specific genetic alterations.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Gene Expression Profiling. Genomics. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cost-Benefit Analysis. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Infant. Infant, Newborn. Male. Patient Selection. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16567768.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA096832
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A: Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol; 2005 Aug 20;23(24):5511-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
  • PURPOSE: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB).
  • [MeSH-major] Achievement. Cerebellar Neoplasms / psychology. Cerebellar Neoplasms / therapy. Cognition Disorders / etiology. Intelligence. Medulloblastoma / psychology. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Longitudinal Studies. Male. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110011.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA21765; United States / NCI NIH HHS / CA / R01CA78957; United States / NCI NIH HHS / CA / U01CA81445
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


60. Aker FV, Ozkara S, Eren P, Peker O, Armağan S, Hakan T: Cerebellar liponeurocytoma/lipidized medulloblastoma. J Neurooncol; 2005 Jan;71(1):53-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for cerebellar liponeurocytoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar liponeurocytoma/lipidized medulloblastoma.
  • Although, basically all reported cases share a similar histological pattern, i.e. focal accumulations of adiposities in an otherwise typical small cell tumor like central neurocytoma, some clinical properties such as (age, proliferative potential, therapy and survival) are not uniform.
  • The exact biological behavior of this special variant tumor is established.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Medulloblastoma / diagnosis. Neoplasms, Adipose Tissue / diagnosis. Neurocytoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Treatment Outcome

  • Genetic Alliance. consumer health - Cerebellar Liponeurocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719276.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 33
  •  go-up   go-down


61. Frankel A, Lau Q, Olson S: Lymph node metastasis of medulloblastoma in a young adult. J Clin Neurosci; 2009 Nov;16(11):1485-6
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node metastasis of medulloblastoma in a young adult.
  • Medulloblastoma is the commonest primary central nervous system malignancy in childhood, but is rare in adults.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / secondary. Lymph Nodes / pathology. Medulloblastoma / pathology. Medulloblastoma / secondary
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581092.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


62. Durando X, Thivat E, Gilliot O, Irthum B, Verrelle P, Vincent C, Bay JO: Temozolomide treatment of an adult with a relapsing medulloblastoma. Cancer Invest; 2007 Sep;25(6):470-5
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment of an adult with a relapsing medulloblastoma.
  • The prognosis of relapsing medulloblastoma is poor and treatment is often difficult, especially after radiotherapy.
  • Here, we report the use of temozolomide in an adult presenting relapsing medulloblastoma.
  • This observation suggests this drug may be useful in medulloblastoma, either as conventional chemotherapy or for use together with radiotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882660.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


63. Gilhuis HJ, van der Laak JA, Pomp J, Kappelle AC, Gijtenbeek JM, Wesseling P: Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis; 2006;9(4):201-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes.
  • In the World Health Organisation (WHO) classification of tumours of the nervous system, four main histopathological subtypes of medulloblastomas (classic medulloblastoma, desmoplastic medulloblastoma, medulloblastoma with extensive nodularity and advanced neuronal differentiation and large cell/anaplastic medulloblastoma) as well as of ependymal tumours (low-grade ependymoma, anaplastic ependymoma, myxopapillary ependymoma and subependymoma) are recognised.
  • Under the hypothesis that the microvascular architecture of tumours is a reflection of the histopathological subtype, we performed three-dimensional reconstructions of the microvasculature in these subtypes of medulloblastomas and ependymal tumours using computerised image analysis.
  • Three-dimensional reconstructions showed a dense pattern of irregular vessels in classic and large cell medulloblastoma.
  • In desmoplastic medulloblastoma and medulloblastoma with extensive nodularity, the vessels were more unevenly distributed and organised around the nodular areas.
  • Classic medulloblastoma and large cell medulloblastoma had on average the largest vessel area and perimeter.
  • The highest number of vessels was seen in classic medulloblastoma and medulloblastoma with extensive nodularity.
  • We conclude that our three-dimensional reconstructions shed unprecedented light on the tumour vasculature in medulloblastomas and ependymal tumours and expect that such reconstructions are helpful tools for further studies on tumour angiogenesis.
  • [MeSH-major] Cerebellar Neoplasms / blood supply. Ependymoma / blood supply. Medulloblastoma / blood supply. Models, Biological
  • [MeSH-minor] Adult. Animals. Humans. Mice. Microcirculation / physiology

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109194.001).
  • [ISSN] 0969-6970
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Dharmaraj P, Ball S, Johnstone H, Bailey S, Clifford SC, Hale J, Cheetham TD: Hypercalcaemia in relapsed medulloblastoma 8 years post-diagnosis; evidence to support PTHrP production by medulloblastoma cells. Horm Res; 2006;66(6):268-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcaemia in relapsed medulloblastoma 8 years post-diagnosis; evidence to support PTHrP production by medulloblastoma cells.
  • BACKGROUND: A 19-year-old male presented with symptomatic hypercalcaemia as the first manifestation of relapsed metastatic medulloblastoma.
  • His biochemistry at the time of relapse and studies of medulloblastoma cell lines provide an insight into the pathogenesis of his hypercalcaemia.
  • METHODS: Parathyroid hormone-related protein (PTHrP) was measured by immunoradiometric assay in blood, and in conditioned and control media from three medulloblastoma cell lines following 72 h growth.
  • RESULTS: The histology at initial presentation (11 years of age) and at the time of relapse (with bone marrow infiltration and widespread bony metastases) demonstrated medulloblastoma.
  • CONCLUSIONS: Relapse 8 years after diagnosis is unusual in medulloblastoma and for this relapse to manifest as hypercalcaemia is also very uncommon.
  • Our investigations suggest that the clinical picture was a reflection of PTHrP production by medulloblastoma cells.
  • [MeSH-major] Bone Neoplasms / secondary. Cerebellar Neoplasms / complications. Hypercalcemia / etiology. Medulloblastoma / complications. Medulloblastoma / metabolism. Parathyroid Hormone-Related Protein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Male. Recurrence


65. Siu IM, Bai R, Gallia GL, Edwards JB, Tyler BM, Eberhart CG, Riggins GJ: Coexpression of neuronatin splice forms promotes medulloblastoma growth. Neuro Oncol; 2008 Oct;10(5):716-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexpression of neuronatin splice forms promotes medulloblastoma growth.
  • Medulloblastoma (MB) is the most common pediatric brain cancer.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1995 Sep;171(1):73-84 [7556909.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3444-53 [15064731.001]
  • [Cites] Brain Res. 1995 Aug 28;690(1):92-8 [7496812.001]
  • [Cites] Brain Res. 1996 Jun 3;723(1-2):8-22 [8813377.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1805-13 [9137103.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3428-32 [9254699.001]
  • [Cites] Dev Biol. 1997 Oct 1;190(1):66-77 [9331332.001]
  • [Cites] J Mol Neurosci. 1997 Aug;9(1):55-60 [9356927.001]
  • [Cites] Genes Dev. 1999 Jul 1;13(13):1647-52 [10398678.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):151-68 [15657362.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):703-7 [15705863.001]
  • [Cites] Diabetes. 2005 Apr;54(4):1064-73 [15793245.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8 [15980575.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):673-81 [16423996.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3019-27 [16707597.001]
  • [Cites] J Thorac Oncol. 2007 Sep;2(9):796-801 [17805055.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Genome Res. 2000 Sep;10(9):1393-402 [10984457.001]
  • [Cites] Dev Biol. 2001 Aug 15;236(2):387-99 [11476579.001]
  • [Cites] Genomics. 2001 Sep;77(1-2):99-104 [11543638.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7687-94 [14576832.001]
  • [Cites] Biol Reprod. 2004 Apr;70(4):1131-5 [14668210.001]
  • [Cites] Science. 1995 Oct 20;270(5235):484-7 [7570003.001]
  • (PMID = 18701710.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS052507-02; United States / NINDS NIH HHS / NS / R01 NS052507; United States / NINDS NIH HHS / NS / NS052507; United States / NINDS NIH HHS / NS / R01 NS052507-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / NNAT protein, human; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2666248
  •  go-up   go-down


66. Shim KW, Joo SY, Kim SH, Choi JU, Kim DS: Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray. J Neurosurg Pediatr; 2008 Mar;1(3):196-205
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray.
  • OBJECTIVES: Medulloblastoma is the most common malignant neuroepithelial tumor found in children.
  • Several reports have described efforts to identify the prognostic significance of various patterns of pathological and immunohistochemical features in medulloblastoma, but the published data appear to be controversial.
  • The authors therefore attempted to demonstrate these prognostic factors convincingly in a retrospective study performed in patients with medulloblastoma.
  • METHODS: The data used were obtained in 58 patients with medulloblastoma who were > 3 years of age and in whom > 1 year of follow-up was available after the maximal resection, craniospinal irradiation, and chemotherapy treatments.
  • In addition, the authors tried to determine the prognostic utility of these results in this tumor category.
  • RESULTS: There was no statistically significant correlation between the prognosis and the degree of cell differentiation, but a positive correlation was noted between the PI and the AI in a tumor mass.
  • The number of cases with a PI > 10% was significantly greater in the group of tumors in patients with recurrent medulloblastoma.
  • Most importantly, the PI is the only significant prognostic factor for the overall survival of patients with medulloblastoma.
  • CONCLUSIONS: Therefore, the authors suggest that the PI is directly linked to the prognostic factor for medulloblastoma and that immunohistochemical staining is a potentially powerful tool for predicting the prognosis of patients with medulloblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Apoptosis / physiology. Cell Differentiation / physiology. Cell Proliferation. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Forecasting. Humans. Immunohistochemistry. Male. Microarray Analysis. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Receptor, ErbB-3 / analysis. Receptor, trkC / analysis. Retrospective Studies. Treatment Outcome


67. Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G, Schindler C, Jones N, Klein-Franke A, Maier H, Jauk B, Kiefer A, Hainfellner JA: Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer; 2006 Nov;42(17):2996-3003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
  • Standard postoperative treatment of medulloblastoma consists of craniospinal irradiation and chemotherapy.
  • In the present study we tested the prognostic influence of four histopathological parameters considered in recent publications as prognostic factors in medulloblastoma.
  • We analysed a series of 82 Austrian medulloblastoma patients who were treated according to the consecutive HIT protocols for medulloblastoma conducted by the German Society of Paediatric Haematology and Oncology.
  • Our data indicate that high survivin expression is related to unfavourable clinical outcome in medulloblastoma patients.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Inhibitor of Apoptosis Proteins. Male. Prognosis. Receptor, ErbB-2 / metabolism. Receptor, trkC / metabolism. Survival Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996732.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


68. Hoffman S, Schellinger KA, Propp JM, McCarthy BJ, Campbell RT, Davis FG: Seasonal variation in incidence of pediatric medulloblastoma in the United States, 1995-2001. Neuroepidemiology; 2007;29(1-2):89-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seasonal variation in incidence of pediatric medulloblastoma in the United States, 1995-2001.
  • BACKGROUND/AIMS: Brain tumors are the second most common pediatric malignancy.
  • The literature suggests that one of the most common subtypes of malignant childhood brain tumor, medulloblastoma, has some seasonal variation in incidence by month of birth.
  • METHODS: Data from cases in the Central Brain Tumor Registry of the United States, including primary brain tumor cases diagnosed in children (0-19 years) between the years 1995 and 2001 from 13 state cancer registries, were analyzed to determine whether there was seasonal variation.
  • RESULTS: Seasonal variation in incidence by month of birth was highly statistically significant for medulloblastoma, not otherwise specified (NOS) (p = 0.016), with the peak occurring in October.
  • Medulloblastoma, NOS also demonstrated seasonal variation in incidence by month of birth in children aged 5-19 (p = 0.041), especially females aged 5-19 (p = 0.034), with the peak in October.
  • There were no significant results for brain tumors overall, or for the other most common pediatric tumor subtypes (pilocytic astrocytoma, other astrocytoma, and ependymoma).
  • CONCLUSION: These preliminary results indicate seasonal variation unique to medulloblastoma incidence by month of birth and may provide evidence for an environmental exposure etiology, though further studies are needed to explore specific hypotheses.
  • [MeSH-major] Cerebellar Neoplasms / epidemiology. Medulloblastoma / epidemiology. Parturition. Seasons
  • [MeSH-minor] Adolescent. Adult. Birth Rate. Child. Child, Preschool. Female. Humans. Incidence. Male. Registries. United States / epidemiology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17925600.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Ng D, Stavrou T, Liu L, Taylor MD, Gold B, Dean M, Kelley MJ, Dubovsky EC, Vezina G, Nicholson HS, Byrne J, Rutka JT, Hogg D, Reaman GH, Goldstein AM: Retrospective family study of childhood medulloblastoma. Am J Med Genet A; 2005 May 1;134(4):399-403
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective family study of childhood medulloblastoma.
  • Medulloblastoma is the most common malignant central nervous system tumor of childhood and can occur sporadically or in association with inherited cancer susceptibility syndromes such as the nevoid basal cell carcinoma syndrome (NBCCS).
  • To determine whether an association existed between the risk of developing medulloblastoma and undiagnosed syndromes, we retrospectively reviewed clinical data on 33 patients with medulloblastoma from a single institution and compared them with their unaffected relatives (n = 46).
  • Two patients with isolated desmoplastic medulloblastoma had an insertion and splice site mutation, respectively, in suppressor of fused (SUFU).
  • All patients with nondesmoplastic medulloblastoma histology received molecular testing for SUFU.
  • We performed a clinical evaluation for Greig cephalopolysyndactyly syndrome (GCPS) in four medulloblastoma families, who exhibited macrocephaly as the only finding consistent with the diagnosis of GCPS.
  • There was a paucity of clinical findings among the majority of medulloblastoma patients in this study group to suggest a definable cancer genetic syndrome.
  • We conclude that clinically recognizable syndromes are uncommon among patients with medulloblastoma, however, PTCH1 and SUFU mutations are present at a low but significant frequency.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. DNA / chemistry. DNA / genetics. DNA Mutational Analysis. DNA-Binding Proteins / genetics. Female. Humans. Infant. Kruppel-Like Transcription Factors. Male. Mutation. Nerve Tissue Proteins / genetics. Pedigree. Receptors, Cell Surface / genetics. Repressor Proteins / genetics. Retrospective Studies. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • [ErratumIn] Am J Med Genet A. 2005 Jul 15;136(2):226
  • (PMID = 15759260.001).
  • [ISSN] 1552-4825
  • [Journal-full-title] American journal of medical genetics. Part A
  • [ISO-abbreviation] Am. J. Med. Genet. A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GLI3 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Receptors, Cell Surface; 0 / Repressor Proteins; 0 / SUFU protein, human; 0 / Transcription Factors; 0 / patched receptors; 9007-49-2 / DNA
  •  go-up   go-down


70. Douglas-Akinwande AC, Payner TD, Hattab EM: Medulloblastoma mimicking Lhermitte-Duclos disease on MRI and CT. Clin Neurol Neurosurg; 2009 Jul;111(6):536-9
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma mimicking Lhermitte-Duclos disease on MRI and CT.
  • BACKGROUND: Although previous reports purport that the unique magnetic resonance imaging (MRI) features of Lhermitte-Duclos disease (LDD) obviates the need for biopsy, medulloblastoma can have an indistinguishable imaging appearance.
  • CASE DESCRIPTION: We present a patient who suffered from a medulloblastoma that demonstrated no enhancement and had imaging characteristics that were indistinguishable from LDD.
  • [MeSH-major] Brain / pathology. Ganglioneuroma / pathology. Hamartoma Syndrome, Multiple / pathology. Infratentorial Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lhermitte-Duclos disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233547.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Gilbertson RJ, Langdon JA, Hollander A, Hernan R, Hogg TL, Gajjar A, Fuller C, Clifford SC: Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer; 2006 Mar;42(5):646-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma.
  • Aberrant signalling via platelet derived growth factor receptors (PDGFRs) and the RAS/MAPK pathway has been implicated in the development of medulloblastoma, the most common malignant brain tumour in childhood.
  • To determine whether genetic mechanisms play a role in the activation of PDGFR-RAS/MAPK signalling in medulloblastoma, we performed a direct sequence analysis of the established mutational "hotspots" of known targets of activating mutations within the pathway (PDGFRA, NRAS, KRAS, HRAS and BRAF) and PDFRFB, in a cohort of 28 primary tumours.
  • A synonymous sequence variation in PDGFRA (CCG to CCA; PRO 567 PRO) was detected in two cases (approximately 7%), but not in 150 normal chromosomes assessed, suggesting that the PDGFRA locus may be associated with medulloblastoma development in certain cases.
  • These data demonstrate that activating mutations in established mutational hotspots within the PDGFR-RAS/MAPK pathway are rare events in medulloblastoma development, and suggest that alternative mechanisms are responsible for RAS/MAPK pathway activation in this disease.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Genes, ras / genetics. Medulloblastoma / genetics. Mitogen-Activated Protein Kinases / genetics. Mutation / genetics. Receptors, Platelet-Derived Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Exons. Female. Humans. Infant. MAP Kinase Signaling System. Male. Polymorphism, Restriction Fragment Length. Receptor, Platelet-Derived Growth Factor alpha / genetics. Receptor, Platelet-Derived Growth Factor alpha / metabolism

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Medulloblastoma, childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434186.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA96832-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


72. Gauchotte G, Baylac F, Marie B, Vignaud JM: [Medullomyoblastoma: a medulloblastoma with rhabdomyoblastic differentiation]. Ann Pathol; 2010 Apr;30(2):135-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medullomyoblastoma: a medulloblastoma with rhabdomyoblastic differentiation].
  • [Transliterated title] Le médullomyoblastome : une variante de médulloblastome avec différenciation rhabdomyoblastique.
  • A 26 years old patient was operated for a tumor of cerebellar vermix, and then reoperated for a relapse at the age of 35 years, with a similar histological pattern in both cases.
  • At pathologic examination, the tumor was composed of hypercellular sheets typical of medulloblastoma, containing also sparse large cells with eosinophilic cytoplasm and round nuclei containing voluminous nucleoli.
  • Medullomyoblastoma is a rare variant of medulloblastoma with a rhabdomyoblastic differentiation.
  • The main differential diagnoses are atypical teratoid/rhabdoid tumor, immature teratoma, medulloepithelioma, primitive intracranial rhabdomyosarcoma and myoneurocytoma.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Differentiation. Desmin / analysis. Disease Progression. Fatal Outcome. Humans. Male. Muscle Cells / chemistry. Muscle Cells / pathology. Myogenin / analysis. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / chemistry. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurofilament Proteins / analysis. Rhabdomyosarcoma / pathology. Synaptophysin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20451073.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Myogenin; 0 / Neoplasm Proteins; 0 / Neurofilament Proteins; 0 / Synaptophysin
  •  go-up   go-down


73. Huse JT, Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer; 2010 May;10(5):319-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma.
  • Malignant brain tumours continue to be the cause of a disproportionate level of morbidity and mortality across a wide range of individuals.
  • The most common variants in the adult and paediatric populations - malignant glioma and medulloblastoma, respectively - have been the subject of increasingly intensive research over the past two decades that has led to considerable advances in the understanding of their basic biology and pathogenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Cerebellar Neoplasms / genetics. Glioma / genetics. Medulloblastoma / genetics. Pathology, Molecular / trends


74. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, Low JA: Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med; 2009 Sep 17;361(12):1173-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
  • Medulloblastoma is the most common malignant brain tumor in children.
  • Aberrant activation of the hedgehog signaling pathway is strongly implicated in the development of some cases of medulloblastoma.
  • A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms.
  • Molecular analyses of tumor specimens obtained before treatment suggested that there was activation of the hedgehog pathway, with loss of heterozygosity and somatic mutation of the gene encoding patched homologue 1 (PTCH1), a key negative regulator of hedgehog signaling.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzimidazoles / therapeutic use. Cerebellar Neoplasms / drug therapy. Hedgehog Proteins / antagonists & inhibitors. Medulloblastoma / drug therapy
  • [MeSH-minor] Adult. Anilides. Gene Expression. Humans. Male. Patched Receptors. Patched-1 Receptor. Polymerase Chain Reaction. Pyridines. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Signal Transduction / drug effects. Transcription Factors / genetics. Transcription Factors / metabolism. Zinc Finger Protein GLI1


75. Piedimonte LR, Wailes IK, Weiner HL: Medulloblastoma: mouse models and novel targeted therapies based on the Sonic hedgehog pathway. Neurosurg Focus; 2005 Nov;19(5):E8
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma: mouse models and novel targeted therapies based on the Sonic hedgehog pathway.
  • In children, tumors of the central nervous system are thought to arise from progenitor cells that show considerable temporal and spatial heterogeneity in a developmental environment that is different from that of the adult.
  • In this review the authors discuss the mouse models based on the Sonic hedgehog pathway, which have provided a better knowledge of the genetic and molecular alterations of medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Disease Models, Animal. Gene Targeting / methods. Medulloblastoma / genetics. Trans-Activators / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398472.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA093450
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Shh protein, mouse; 0 / Trans-Activators
  • [Number-of-references] 64
  •  go-up   go-down


76. Lew SM, Morgan JN, Psaty E, Lefton DR, Allen JC, Abbott R: Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma. J Neurosurg; 2006 Feb;104(2 Suppl):103-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma.
  • OBJECT: The goal of this study was to determine the incidence of radiation-induced cavernomas in children treated for medulloblastoma.
  • METHODS: A retrospective chart and film review was performed for all patients treated for medulloblastoma at the Insitute for Neurology and Neurosurgery/Beth Israel Medical Center between August 1996 and the present.
  • The clinical and radiographic histories of pediatric patients (ages 3-21 years at diagnosis) with a histologically confirmed diagnosis of medulloblastoma who received craniospinal radiation therapy were reviewed.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Hemangioma, Cavernous / etiology. Medulloblastoma / radiotherapy. Radiation Injuries
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cranial Irradiation / adverse effects. Female. Humans. Incidence. Male. Retrospective Studies. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506497.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Wallin JL, Tanna N, Misra S, Puri PK, Sadeghi N: Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome. Am J Otolaryngol; 2007 Sep-Oct;28(5):360-2
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal carcinoma after irradiation for medulloblastoma in nevoid basal cell carcinoma syndrome.
  • BACKGROUND: Nevoid basal cell carcinoma syndrome (NBCCS) is associated with multiple basal cell carcinomas, odontogenic cysts, craniofacial anomalies, and childhood medulloblastomas.
  • METHODS: We present a 19-year-old man with NBCCS who presented with a sinonasal carcinoma 17 years after receiving craniospinal irradiation for treatment of medulloblastoma.
  • RESULTS: To our knowledge, this is the first report of a sinonasal tumor after irradiation in a patient with NBCCS.
  • In addition, the management of neoplasms in these tumor-sensitive patients is reviewed.
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / radiotherapy

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826543.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Roldán G, Brasher P, Vecil G, Senger D, Rewcastle B, Cairncross G, Forsyth P, Hamilton M: Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996. Can J Neurol Sci; 2008 May;35(2):210-5
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996.
  • BACKGROUND: The purpose of this study was to determine incidence, survival rate, and prognostic factors as well as the frequency of Collins' Law Violators (CLVs) in an unselected population of medulloblastoma patients.
  • Collins' Law dictates that 'cure' of a child with a tumor occurs after a period that includes the child's age at diagnosis plus 9 months.
  • METHODS: Using the Alberta Cancer Registry a population-based review identified 49 patients with medulloblastoma (19 adults, 30 children) diagnosed from 1975-96.
  • Tumor recurrence occurred a median of 22.4 months (range, 6.4-192.3) after diagnosis and median survival after recurrence was 9.3 months (range, 0.4-64.9).
  • The survival curve did not appear to plateau but was affected by tumor-related deaths in 3 (21.4%) of the 21 long-term survivors diagnosed in childhood.
  • CONCLUSIONS: The survival rate in an unselected population of patients with medulloblastoma is poor.
  • The Collins' Law Violators were relatively common and we suggest this concept be abandoned in medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / epidemiology. Medulloblastoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Alberta / epidemiology. Child. Child, Preschool. Community Health Planning. Female. Humans. Infant. Longitudinal Studies. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574936.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


79. Shu XH, Li H, Sun Z, Wu ML, Ma JX, Wang JM, Wang Q, Sun Y, Fu YS, Chen XY, Kong QY, Liu J: Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol; 2010 May 15;79(10):1516-25
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells.
  • This issue was addressed here by identifying the metabolic pattern and the bioactive form of resveratrol in a resveratrol-sensitive human medulloblastoma cell line, UW228-3.
  • The cell lysates and condition media of UW228-3 cells with or without 100 microM resveratrol treatment were analyzed by HPLC and LC/MS which revealed (1) that resveratrol was chemically unstable and the spontaneous generation of cis-resveratrol reduced resveratrol's anti-medulloblastoma efficacy and (2) that resveratrol monosulfate was the major metabolite of the cells.
  • To identify the bioactive form of resveratrol, a mixture-containing approximately half fraction of resveratrol monosulfate was prepared by incubating trans-resveratrol with freshly prepared rat brain lysates.
  • Medulloblastoma cells treated by 100 microM of this mixture showed attenuated cell crisis.
  • The overall levels of the three brain-associated sulfotransferases (SULT1A1, 1C2 and 4A1) were low in medulloblastoma cells in vivo and in vitro in comparison with that in human noncancerous and rat normal cerebella; resveratrol could more or less up-regulate the production of these enzymes in UW228-3 cells but their overall level was still lower than that in normal cerebellum tissue.
  • Our study thus demonstrated for the first time that trans-resveratrol is the bioactive form in medulloblastoma cells in which the expression of brain-associated SULTs was down-regulated, resulting in the increased intracellular bioavailability and anti-medulloblastoma efficacy of trans-resveratrol.
  • [MeSH-major] Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy. Stilbenes / pharmacokinetics
  • [MeSH-minor] Adolescent. Animals. Biotransformation. Blotting, Western. Cell Line, Tumor. Child. Chromatography, High Pressure Liquid. Humans. Rats. Reverse Transcriptase Polymerase Chain Reaction. Sulfotransferases / metabolism. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105429.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Stilbenes; EC 2.8.2.- / Sulfotransferases; Q369O8926L / resveratrol
  •  go-up   go-down


80. Teglund S, Toftgård R: Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta; 2010 Apr;1805(2):181-208
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog beyond medulloblastoma and basal cell carcinoma.
  • The Hedgehog (Hh) signaling pathway is of central importance during embryo development in metazoans and governs a diverse array of processes including cell proliferation, differentiation, and tissue patterning.
  • In normal adult physiology, the pathway is implicated in stem cell maintenance, tissue repair and regeneration.
  • The Hh pathway is firmly linked to the etiology of basal cell carcinoma and to at least a subset of medulloblastoma.
  • In this review, we provide an overview of the pathway's role in various tumor types, where much of the framework for Hh-dependent malignancies has been elucidated in experimental mouse models.
  • [MeSH-major] Brain Neoplasms / metabolism. Carcinoma, Basal Cell / metabolism. Hedgehog Proteins / metabolism. Medulloblastoma / metabolism. Signal Transduction / physiology. Skin Neoplasms / metabolism


81. Roland JT Jr, Cosetti M, Liebman T, Waltzman S, Allen JC: Cochlear implantation following treatment for medulloblastoma. Laryngoscope; 2010 Jan;120(1):139-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cochlear implantation following treatment for medulloblastoma.
  • OBJECTIVES/HYPOTHESIS: Medulloblastoma is the most common pediatric malignant tumor of the central nervous system in children.
  • Issues of CI in this population, including diagnosis, treatment of preoperative middle ear disease, operative and postoperative course, performance data, and long-term tumor surveillance are highlighted and reviewed.
  • METHODS: Three patients treated for pediatric medulloblastoma with surgical resection, postoperative hyperfractioned craniospinal radiotherapy, and multiagent adjuvant chemotherapy who underwent cochlear implantation were identified.
  • CONCLUSIONS: Patients treated for pediatric medulloblastoma develop otologic sequelae, including profound SNHL, and may require cochlear implantation.
  • [MeSH-major] Brain Neoplasms / therapy. Cochlear Implantation. Hearing Loss, Sensorineural / surgery. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Humans. Retrospective Studies. Treatment Outcome


82. Pierson J, Hostager B, Fan R, Vibhakar R: Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol; 2008 Oct;90(1):1-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma.
  • Despite recent advances in treatment medulloblastoma continues to remain a vexing problem.
  • Recently increased expression of cyclin dependent kinase 6 (CDK6) was identified as an adverse prognostic marker in medulloblastoma.
  • We hypothesized that CDK6 expression is also regulated by microRNAs in medulloblastoma.
  • We identified putative miR sites in the CDK6 including microRNA 124a, a brain enriched microRNA.
  • Expression of miR 124a was significantly decreased in medulloblastoma cells compared to normal adult cerebellum.
  • Functional association between miR 124a and CDK6 in medulloblastoma was established using luciferase assays.
  • Additionally, re-expression of miR 124a in medulloblastoma cells decreased expression of CDK6 protein.
  • Transfection of miR 124 significantly decreases medulloblastoma cell growth but does not alter apoptosis.
  • Our data strongly indicate that CDK6 is regulated by microRNA 124 in medulloblastoma and that miR 124 modulates medulloblastoma cell growth.
  • [MeSH-major] Brain Neoplasms / genetics. Cyclin-Dependent Kinase 6 / genetics. Gene Expression Regulation, Neoplastic. Medulloblastoma / genetics. MicroRNAs / genetics
  • [MeSH-minor] Apoptosis / physiology. Base Sequence. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Humans. Molecular Sequence Data. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607543.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  •  go-up   go-down


83. Pizer BL, Clifford SC: The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg; 2009 Aug;23(4):364-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
  • Medulloblastoma is the most common malignant brain tumour of childhood and accounts for around 10% of all childhood cancer deaths.
  • Pan-European clinical trials being planned for medulloblastoma by the SIOP Brain tumour group will assess the stratification of patients using molecular and histological biomarkers, alongside clinical indices, to select favourable, standard and high-risk treatment groups.
  • The implementation of these trials presents important new logistical challenges within routine practice, involving (i) the development of quality-controlled sample collection and handling systems across multiple treatment centres, including the mandatory ascertainment of fresh-frozen tumour material, and (ii) the delivery of standardised central biomarker analysis and histopathological review, within the approximately 30-day post-surgical window, prior to the selection and commencement of adjuvant therapy.
  • Their success will require a coordinated approach by the entire multidisciplinary team, including neurosurgeons, oncologists and neuropathologists, with the common aim of facilitating targeted delivery of individualised risk-adapted therapies for children with medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms. Clinical Trials as Topic. Medulloblastoma. Patient Selection
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Europe / epidemiology. Feasibility Studies. Female. Humans. Intercellular Signaling Peptides and Proteins / physiology. Male. Mutation. Prognosis. Signal Transduction. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19637007.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins
  • [Number-of-references] 86
  •  go-up   go-down


84. Sanders RP, Onar A, Boyett JM, Broniscer A, Morris EB, Qaddoumi I, Armstrong GT, Boop FA, Sanford RA, Kun LE, Merchant TE, Gajjar A: M1 Medulloblastoma: high risk at any age. J Neurooncol; 2008 Dec;90(3):351-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] M1 Medulloblastoma: high risk at any age.
  • BACKGROUND: The prognosis for children with M1 medulloblastoma (positive CSF cytology) has not been well-defined.
  • METHODS: We retrospectively reviewed the records of 285 newly diagnosed medulloblastoma patients treated between 1984 and 2006.
  • Older children received post-operative craniospinal and tumor bed irradiation; radiotherapy for younger children depended on treatment era and physician/family preference.
  • CONCLUSIONS: Children <3 years old with M1 medulloblastoma fared poorly in our small series.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):152-61 [11554387.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2762-7 [7743483.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4881-7 [15611503.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):525-31 [15659498.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] Lancet Oncol. 2005 Aug;6(8):573-80 [16054568.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • (PMID = 18704266.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS64362; NLM/ PMC2597631
  •  go-up   go-down


85. Yang LS, Wang YQ, Huang FP: [Correlation between the prognosis of medulloblastoma and relevant clinical factors: analysis of 73 cases]. Zhonghua Yi Xue Za Zhi; 2007 May 22;87(19):1322-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between the prognosis of medulloblastoma and relevant clinical factors: analysis of 73 cases].
  • OBJECTIVE: To analyze the correlation between the prognosis of medulloblastoma (MB) and relevant clinical factors.
  • The correlation between the prognosis and the clinical factors, such and sex, age, tumor location, extent of tumor resection, brainstem invasion, radiotherapy, chemotherapy, ventriculoperitoneal shunt and glial differentiation was analyzed.
  • Those undergoing whole brain/posterior fossa plus spinal axis radiotherapy showed a better prognosis than those undergoing whole brain/posterior fossa radiotherapy.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727776.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Sun YJ, Yu SZ, Sun CY, Wang Q, Jin SM, Wu WX, An TL: [Detection of chromosomal DNA imbalance in medulloblastoma by comparative genomic hybridization]. Zhonghua Bing Li Xue Za Zhi; 2010 Sep;39(9):606-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of chromosomal DNA imbalance in medulloblastoma by comparative genomic hybridization].
  • OBJECTIVE: To investigate the relationship between chromosomal genomic DNA imbalance in medulloblastoma (MB), and the age and gender.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Female. Humans. Male. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092588.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


87. Mühlisch J, Bajanowski T, Rickert CH, Roggendorf W, Würthwein G, Jürgens H, Frühwald MC: Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol; 2007 May;83(1):17-29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses.
  • Certain risk groups among tumors of the central nervous system (CNS) in children take an almost inevitably fatal course.
  • Aberrant methylation is common in malignant brain tumors of childhood and may have implications for stratification and therapy.
  • Methylation of p16 (INK4A), p14 (ARF), TIMP3, CDH1, p15 (INK4B )and DAPK1 in medulloblastoma (MB) and ependymoma has been discussed controversially in the literature.
  • Only p16 (INK4A )and TIMP3 were methylated consistently in medulloblastomas (p16 (INK4A ) 14%, TIMP3 11%) and p16 (INK4A) also in anaplastic ependymomas (1/4 tumors).
  • Therapeutic and diagnostic implications urge into depth analyses of methylation as a mechanism, which might fill some of the gaps of our understanding of brain tumor origin.
  • [MeSH-major] Brain Neoplasms / genetics. Cerebellar Neoplasms / genetics. DNA Methylation. Genes, p16. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Tissue Inhibitor of Metalloproteinase-3 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Child. Child, Preschool. Death-Associated Protein Kinases. Female. Gene Silencing. Humans. Infant. Male. Middle Aged. Nerve Tissue Proteins / genetics. Receptors, Immunologic / genetics

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206475.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Immunologic; 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3; 0 / roundabout protein; EC 2.7.11.1 / DAPK1 protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


88. Wolff JE, Hüttermann U, Askins MA: Quantifying health status outcomes in pediatric medulloblastoma patients. Anticancer Res; 2007 Jan-Feb;27(1B):523-9
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantifying health status outcomes in pediatric medulloblastoma patients.
  • BACKGROUND: Comprehensive, efficient health status assessment tools are needed for multi-center studies examining childhood brain tumor treatment outcomes.
  • PATIENTS AND METHODS: The FMH was compared with the medical assessments, intelligence scores, and behavioral/emotional adjustment scores of 21 survivors of medulloblastoma to examine the instrument's feasibility and discriminate validity.
  • CONCLUSION: The FMH is useful as an objective, easily administered measure of health status in brain tumor patients.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Health Status. Medulloblastoma / therapy. Outcome Assessment (Health Care) / methods. Surveys and Questionnaires
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17348436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


89. Chang Q, Ng HK: [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor]. Zhonghua Bing Li Xue Za Zhi; 2007 Jan;36(1):24-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
  • OBJECTIVE: To investigate the epigenetic involvement of RASSF1A in intracranial primitive neuroectodermal tumors (PNETs) and compare the methylation patterns between medulloblastoma (MBs) and supratentorial PNETs (SPNETs).
  • These results demonstrated that such epigenetic alteration was tumor-specific.
  • [MeSH-major] Brain Neoplasms / genetics. Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. DNA Methylation. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. HeLa Cells. Humans. Infant. Male. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult


90. Ribi K, Relly C, Landolt MA, Alber FD, Boltshauser E, Grotzer MA: Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics; 2005 Dec;36(6):357-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of medulloblastoma in children: long-term complications and quality of life.
  • To study the outcomes in long-term survivors of paediatric medulloblastoma (MB), we followed 51 consecutive children who were treated between 1980 and 2000 in a single institution.
  • [MeSH-major] Cerebellar Neoplasms / psychology. Medulloblastoma / psychology. Outcome Assessment (Health Care). Quality of Life
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Child. Disease Progression. Endocrine System / physiopathology. Female. Humans. Intelligence. Interviews as Topic. Longitudinal Studies. Male. Neurologic Examination. Neuropsychological Tests. Retrospective Studies. Social Behavior. Statistics, Nonparametric. Surveys and Questionnaires. Time Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429375.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


91. Korah MP, Esiashvili N, Mazewski CM, Hudgins RJ, Tighiouart M, Janss AJ, Schwaibold FP, Crocker IR, Curran WJ Jr, Marcus RB Jr: Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):106-12
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.
  • PURPOSE: To investigate the incidence, risks, severity, and sequelae of posterior fossa syndrome (PFS) in children with medulloblastoma.
  • METHODS AND MATERIALS: Between 1990 and 2007, 63 children with medulloblastoma at Emory University and Children's Healthcare of Atlanta were treated with craniectomy followed by radiation.
  • Five patients had <1.5-cm(2) residual tumor, 4 had >or=1.5-cm(2) residual tumor, and the remainder had no residual tumor.
  • On univariate analysis, brainstem invasion, midline tumor location, younger age, and the absence of radiographic residual tumor were found to be predictors of PFS; the last two variables remained significant on multivariate analysis.
  • From 1990 to 2000 and from 2001 to 2007, the proportions of patients with no radiographic residual tumor were 77% and 94%, respectively.
  • With the increased incidence of PFS and the permanent morbidity in many patients, the risks and benefits of complete tumor removal in all patients need to be reexamined.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Ataxia / epidemiology. Ataxia / etiology. Child. Child, Preschool. Combined Modality Therapy / methods. Cranial Irradiation. Disease-Free Survival. Dysarthria / epidemiology. Dysarthria / etiology. Female. Follow-Up Studies. Humans. Incidence. Male. Muscle Hypotonia / epidemiology. Muscle Hypotonia / etiology. Mutism / epidemiology. Mutism / etiology. Neoplasm, Residual. Postoperative Complications / epidemiology. Radiotherapy Dosage. Retrospective Studies. Risk. Syndrome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19695790.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Hope AJ, Mansur DB, Tu PH, Simpson JR: Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst; 2006 Sep;22(9):1201-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma.
  • INTRODUCTION: Malignant brain tumors have been reported to occur after childhood irradiation more frequently than in the nonirradiated population.
  • DISCUSSION: In this study, we report the case of a 15-year-old boy treated for medulloblastoma with surgery and craniospinal radiotherapy, who developed a meningioma 18 years after initial treatment and subsequently an anaplastic astrocytoma 23 years after primary treatment.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / radiotherapy. Cranial Irradiation / adverse effects. Medulloblastoma / radiotherapy. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiotherapy Dosage. Radiotherapy, Adjuvant. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570196.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


93. Saran F, Baumert BG, Creak AL, Warrington AP, Ashley S, Traish D, Brada M: Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET. Pediatr Blood Cancer; 2008 Mar;50(3):554-60
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
  • PURPOSE: To evaluate the efficacy and toxicity of hypofractionated stereotactic radiotherapy in the management of locally recurrent or residual central nervous system (CNS) primitive neuroectodermal tumors (PNETs).
  • PATIENTS AND METHODS: Between 1991 and 2005, 12 patients with locally recurrent medulloblastoma and two patients with residual supratentorial PNET were treated with hypofractionated stereotactic conformal radiotherapy (SCRT).
  • Causes of death were recurrent CNS disease (n = 7), herpes encephalitis (n = 1), and metastatic PNET outside the CNS (n = 1).
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Dose Fractionation. Medulloblastoma / radiotherapy. Neuroectodermal Tumors, Primitive / radiotherapy. Radiotherapy, Conformal / methods. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Recurrence, Local / radiotherapy. Neoplasm, Residual. Palliative Care. Retrospective Studies. Stereotaxic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17941071.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, Sterba J: p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol; 2007 Dec;114(6):641-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival.
  • Recently, several TP73 transcripts have been revealed in medulloblastoma (MB), the most common malignant brain tumor in children.
  • We report significant differences for TAp73 and DeltaNp73 mRNA expression between tumor tissues and reference (P = 0.013, P = 0.028).
  • In normal cerebellum, positive staining for p73alpha and DeltaNp73 was observed in the Purkinje cells of newborns, not adult samples, which supports the developmental role of TP73 during organogenesis of the human cerebellum.
  • Our results indicate the involvement of p73 protein in MB tumorigenesis and define TP73 as a potential prognostic and therapeutic target for medulloblastoma.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Medulloblastoma / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Brain / metabolism. Brain / pathology. Brain / physiopathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Immunohistochemistry. Male. Prognosis. Protein Isoforms / genetics. Protein Isoforms / isolation & purification. Protein Isoforms / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Neuropathol. 2008 Nov;116(5):579-80
  • (PMID = 17912537.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


95. Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastri D, Ravagnani F, Fossati-Bellani F: No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma. Int J Radiat Oncol Biol Phys; 2009 Apr 1;73(5):1358-63
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
  • PURPOSE: Myeloablative regimens were frequently used for medulloblastoma relapsing after craniospinal irradiation (CSI): in 1997-2002, we used repeated surgery, standard-dose and myeloablative chemotherapy, and reirradiation.
  • RESULTS: Seventeen patients were treated: previous treatment included CSI of 19.5-36 Gy with posterior fossa/tumor boost and chemotherapy in 16 patients.
  • Relapse sites included leptomeninges in 9 patients, spine in 4 patients, posterior fossa in 3 patients, and brain in 1 patient.
  • Twelve of 14 patients with assessable tumor had an objective response after reinduction; 2 experienced progression and were not given the myeloablative courses.
  • A salvage therapy for medulloblastoma after CSI still needs to be sought.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms. Medulloblastoma. Neoplasm Recurrence, Local. Salvage Therapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Carboplatin / adverse effects. Child. Child, Preschool. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy / methods. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Radiotherapy Dosage. Remission Induction / methods. Thiotepa / administration & dosage. Thiotepa / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019566.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


96. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ, Marie SK: Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun; 2008;8:7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-testis (CT) antigen expression in medulloblastoma.
  • Medulloblastoma is the most common childhood malignant tumor of the central nervous system.
  • Treatment of medulloblastoma requires harmful therapy and nevertheless carries a poor prognosis.
  • Due to their presence in various cancers and their limited expression in normal tissues, CT antigens are ideal vaccine targets for tumor immunotherapy.
  • CT antigens, such as MAGE and NY-ESO-1, have been employed in clinical trials in various malignancies but little is known about their presence in medulloblastoma.
  • We analyzed 25 medulloblastomas for the expression of a panel of CT antigens by RT-PCR and immunohistochemistry.
  • The absence of correlation between mRNA and protein expression in medulloblastoma has not been observed in other tumors and further studies addressing the biology of CT antigens are necessary to investigate the present discrepant results.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Cerebellar Neoplasms / immunology. Medulloblastoma / immunology
  • [MeSH-minor] Adult. Cancer Vaccines. Child. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Membrane Proteins / biosynthesis. Membrane Proteins / genetics. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. RNA Processing, Post-Transcriptional / genetics. RNA, Messenger / metabolism. Testis / metabolism. Testis / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 2006;24:175-208 [16551247.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):696-703 [16094643.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1089-98 [16596224.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5442-7 [17000678.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):67-74 [17019710.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1218-25 [16929165.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):337-43 [17066423.001]
  • [Cites] Childs Nerv Syst. 2007 Apr;23(4):399-405 [17119978.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2411-7 [17294444.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):726-32 [10699956.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):493-7 [10945497.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):441-50 [11291084.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4809-14 [11406556.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):713-20 [11531257.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6682-7 [11559535.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):839-45 [12115486.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):380-7 [12432251.001]
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):583-8 [12494904.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):167-73 [12538465.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:1 [12747762.001]
  • [Cites] Cancer Immun. 2002 Sep 19;2:11 [12747756.001]
  • [Cites] Lab Invest. 2003 Aug;83(8):1185-92 [12920247.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):376-85 [12946027.001]
  • [Cites] Cancer Immun. 2004 Jan 23;4:1 [14738373.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):568-75 [14991579.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):698-702 [14999777.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4980-6 [15256472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 [15252201.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):527-8 [8509230.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):375-80 [7591235.001]
  • [Cites] Int J Cancer. 1996 Oct 21;69(5):403-7 [8900375.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):743-52 [9485030.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • [Cites] Childs Nerv Syst. 1998 Jun;14(6):256-62 [9694337.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):335-41 [10037183.001]
  • [Cites] Cancer Immun. 2004 Nov 17;4:13 [15546177.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):119-26 [15272278.001]
  • [Cites] Neurosci Lett. 2005 Jun 10-17;381(1-2):69-73 [15882792.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8055-62 [16299236.001]
  • [Cites] Cancer Immun. 2006;6:7 [16594646.001]
  • (PMID = 18426187.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Cancer Vaccines; 0 / MAGEA3 protein, human; 0 / MAGEC1 protein, human; 0 / MAGEC2 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2935780
  •  go-up   go-down


97. Lueth M, von Deimling A, Pietsch T, Wong LJ, Kurtz A, Henze G, Driever PH: Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region. J Pediatr Hematol Oncol; 2010 Mar;32(2):156-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma harbor somatic mitochondrial DNA mutations in the D-loop region.
  • Despite the growing knowledge on molecular risk factors of the most common malignant brain tumor in childhood, medulloblastoma, its biology remains only partially understood.
  • A previous study investigating the entire mitochondrial genome of medulloblastoma revealed a number of somatic mutations in tumor and corresponding cerebrospinal fluid samples.
  • In our present study we sought to corroborate these results on somatic and germ line mutations by comparing the complete mitochondrial genome sequences of medulloblastoma tissue in a further cohort of patients.
  • Analysis of the entire mitochondrial genome by temporal temperature gel electrophoresis and direct sequencing revealed 6 somatic mutations in 6 of 15 medulloblastoma.
  • These results are in support of our previous findings on frequency of somatic mitochondrial mutations in medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. DNA, Mitochondrial / genetics. Medulloblastoma / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Genome, Mitochondrial. Humans. Infant. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20147852.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Mitochondrial
  •  go-up   go-down


98. Akhaddar A, Belhachmi A, Elasri A, Boulahroud O, Okacha N, Elmostarshid B, Boucetta M: [Cerebellar mutism after removal of a vermian medulloblastoma in an adult]. Neurochirurgie; 2008 Aug;54(4):548-50
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebellar mutism after removal of a vermian medulloblastoma in an adult].
  • Histological examination showed a medulloblastoma.
  • The tumor was totally removed via a suboccipital approach.
  • Although pathophysiology and the anatomical substrate of cerebellar mutism still remain unclear, it is important that neurosurgeons be aware of this syndrome after posterior fossa surgery in adults.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Medulloblastoma / surgery. Mutism / etiology. Postoperative Complications
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18495179.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


99. Kadota RP, Mahoney DH, Doyle J, Duerst R, Friedman H, Holmes E, Kun L, Zhou T, Pollack IF: Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. Pediatr Blood Cancer; 2008 Nov;51(5):675-8
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.
  • PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells.
  • There were 6 medulloblastoma and 3 germinoma survivors with a median follow-up of 7.5 years (range = 2.8-10).
  • CONCLUSION: Myeloablative chemotherapy consisting of cyclophosphamide and melphalan was tolerable in the relapsed brain tumor setting with 19/29 cases achieving CR or CCR status and 9/29 becoming long-term survivors.

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81 [11464982.001]
  • [Cites] Neuro Oncol. 2003 Oct;5(4):261-7 [14565163.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1814-23 [9164190.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1199-204 [10098759.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4622-7 [17925558.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):273-8 [16195803.001]
  • [Cites] Expert Rev Neurother. 2006 May;6(5):765-79 [16734524.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2291-7 [17019740.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):285-91 [16598761.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • (PMID = 18623206.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543-06; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098413-06; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098413-06; None / None / / U10 CA098543-06
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS123029; NLM/ PMC2900925
  •  go-up   go-down


100. Riazmontazer N, Daneshbod Y: Cytology of desmoplastic medulloblastoma in imprint smears: a report of 2 cases. Acta Cytol; 2006 Jan-Feb;50(1):97-100
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of desmoplastic medulloblastoma in imprint smears: a report of 2 cases.
  • BACKGROUND: Desmoplastic medulloblastoma is a rare subtype of medulloblastoma with astroglial differentiation.
  • The cytomorphologic features in intraoperative imprint smears from 2 cases of desmoplastic medulloblastoma are described.
  • CASE REPORTS: A 22-year-old man and 27-year-old woman with a cerebellar tumor underwent craniotomy and tumor resection.
  • The cytology was misinterpreted as glial tumors, while the final histologic diagnosis in both cases were desmoplastic medulloblastoma.
  • CONCLUSION: Desmoplastic medulloblastoma shows distinctive cytology in intraoperative smears.
  • However, the occurrence of this rare type in adults and the presence of astroglial elements in imprint smears may cause a cytologic misinterpretation as gliomas.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Astrocytes / pathology. Brain Neoplasms / diagnosis. Diagnostic Errors. Female. Glioma / diagnosis. Humans. Intraoperative Period. Male. Neurons / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514849.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement